Amyloidosis in Every Corner of the World: Bridging Global Knowledge with Regional Challenges
Saturday, November 14, 2026
11:30 AM - 12:00 PM
Foyer Conference Room
Lunch for IKMG Attendees
12:00 PM - 5:00 PM
Conference Room
IKMG Meeting (Non-CME) (separate registration required)
12:00 PM - 12:10 PM
Welcome and Housekeeping
12:10 PM - 12:35 PM
Classification - MGRS Path Classification With Emphasis on New Entities (Membranous, LC Crystalline, LC ITG)
Speaker:
Samih Nasr (USA)
12:35 PM - 12:55 PM
Classification - Renal Lesions That Occur as MGRS and as Separate Disease Entity (non-MGRS)
Speaker:
Nelson Leung (USA)
12:55 PM - 1:15 PM
Classification - Discussion
1:15 PM - 1:20 PM
PGNMID - Case
1:20 PM - 1:40 PM
PGNMID - New Classification, Path
Speaker:
Guillermo Herrera (USA)
1:40 PM - 1:55 PM
PGNMID - Treatment
Speaker:
Estelle Desport (France)
1:55 PM - 2:15 PM
PGNMID - Discussion
2:15 PM - 2:45 PM
Coffee Break
2:45 PM - 3:00 PM
C3/TMA - Case
3:00 PM - 3:15 PM
C3/TMA - Pathology
Speaker:
Maria Picken (USA)
3:15 PM - 3:35 PM
C3/TMA - Novel Treatment
Speaker:
Luis Quintana (Spain)
3:35 PM - 3:55 PM
C3/TMA - Discussion
3:55 PM - 4:00 PM
MIDD - Case
4:00 PM - 4:15 PM
MIDD - Pathology
Speaker:
Virginie Royal (Canada)
4:15 PM - 4:30 PM
MIDD - Response Criteria—IKMG - Experience and a Review
Speaker:
Paolo Milani (Italy)
4:30 PM - 4:50 PM
MIDD - Discussion
Sunday, November 15, 2026
8:00 AM - 12:00 PM
Conference Room
IKMG Meeting (Non-CME) (separate registration required)
8:00 AM - 8:20 AM
Therapies Crossing the Spectrum - Renal Transplant and Recurrence Post-transplant, Use of IMIDs and T Cell Redirecting Therapies
Speaker:
Heather Landau (USA)
8:20 AM - 8:40 AM
Therapies Crossing the Spectrum - CAR-T and Bispecific T-cell Engagers in MGCS and MM
Speaker:
Efstathios Kastritis (Greece)
8:40 AM - 8:55 AM
Therapies Crossing the Spectrum - Discussion
8:55 AM - 9:15 AM
MGCS: POEMS - Diagnosis and Treatment
Speaker:
Angela Dispenzieri (USA)
9:15 AM - 9:35 AM
MGCS: POEMS - Clone and Pathogenesis
Speaker:
Christophe Sirac (France)
9:35 AM - 9:50 AM
MGCS: POEMS - Future Directions / Discussion
Speaker:
Arnaud Jaccard (France)
9:50 AM - 10:05 AM
Coffee Break
10:05 AM - 10:50 AM
Abstract Presentations
Moderator:
Giovanni Palladini (Italy)
10:50 AM - 10:55 AM
Bridoux Award for Best Abstract
10:55 AM - 11:55 AM
Business Meeting
11:55 AM - 12:00 PM
Closing Remarks
Speaker:
Virginie Royal (Canada)
12:00 PM - 12:30 PM
Foyer
Lunch for Masterclass Attendees
12:30 PM - 1:30 PM
Grand Ballroom
MasterClass – Fundamentals of Amyloidosis - Diagnosing Amyloidosis
Moderators:
Eli Muchtar (Israel) & Jose Nativi Nicolau (USA)
12:30 PM - 12:45 PM
Introduction & Classification/Nomenclature
Speaker:
Eli Muchtar (Israel)
12:45 PM - 1:05 PM
When to Suspect Amyloidosis: Red Flag Signs
Speaker:
Jose Nativi Nicolau (USA)
1:05 PM - 1:20 PM
Stepwise Diagnostic Algorithm, Accuracy of Tools, Biopsy vs. Non-biopsy Approaches and Importance of Precise Amyloid Typing
Speaker:
Prem Soman (USA)
1:20 PM - 1:30 PM
Discussion
1:30 PM - 2:30 PM
Grand Ballroom
MasterClass – Fundamentals of Amyloidosis - Management of AL Amyloidosis
Moderators:
Eli Muchtar (Israel) & Vaishali Sanchorawala (USA)
1:30 PM - 1:40 PM
Staging and Risk Stratification in AL Amyloidosis
Speaker:
Vaishali Sanchorawala (USA)
1:40 PM - 2:00 PM
Current Therapies in AL Amyloidosis
Speaker:
Phillip Scheinberg (Brazil)
2:00 PM - 2:15 PM
Approach to Patients with Advanced AL Amyloidosis
Speaker:
Eli Muchtar (Israel)
2:15 PM - 2:30 PM
Discussion: Challenges of AL Therapies and Clinical Trials
Speaker:
Vaishali Sanchorawala (USA)
2:30 PM - 2:45 PM
Foyer
Coffee Break
2:45 PM - 3:45 PM
Grand Ballroom
MasterClass – Fundamentals of Amyloidosis - Management of ATTR Amyloidosis
Moderators:
Faizi Jamal (USA) & Marcia Waddington (Brazil)
2:45 PM - 2:55 PM
Epidemiology and Early Diagnosis
Speaker:
Prem Soman (USA)
2:55 PM - 3:15 PM
ATTR-CM
Speaker:
Faizi Jamal (USA)
3:10 PM - 3:25 PM
ATTR-PN
Speaker:
Marcia Waddington (Brazil)
3:25 PM - 3:35 PM
Genetic Testing and Counseling
Speaker:
Lucas Pereira (USA)
3:35 PM - 3:45 PM
Discussion: Sequencing of TTR Stabilizers and Silencers and Financial Burden of High-cost Drugs
Speakers:
Faizi Jamal (USA), Eli Muchtar (Israel), Jose Nativi Nicolau (USA), Lucas Pereira (USA), Vaishali Sanchorawala (USA), Phillip Scheinberg (Brazil), Prem Soman (USA) & Marcia Waddington (Brazil)
6:00 PM - 6:15 PM
Teatro Solis - Reconquista S / N esq, 3QRX+WHR, Bartolomé Mitre, 11000 Montevideo,
Opening Ceremony and Robert Kyle Remembrance (Non-CME)
6:15 PM - 6:30 PM
Teatro Solis - Reconquista S / N esq, 3QRX+WHR, Bartolomé Mitre, 11000 Montevideo,
Presentation of the Merlini Award (Non-CME)
6:30 PM - 7:00 PM
Teatro Solis - Reconquista S / N esq, 3QRX+WHR, Bartolomé Mitre, 11000 Montevideo,
Merlini Award Lecture (Non-CME)
Speaker:
Morie Gertz (USA)
7:00 PM - 7:30 PM
Teatro Solis - Reconquista S / N esq, 3QRX+WHR, Bartolomé Mitre, 11000 Montevideo,
Invited Keynote Lecture - From Alzheimer to Systemic Amyloidosis: The Rise of Blood Biomarkers (Non-CME)
Speaker:
Mathias Jucker (Germany)
7:30 PM - 9:00 PM
Teatro Solis - Reconquista S / N esq, 3QRX+WHR, Bartolomé Mitre, 11000 Montevideo,
Networking Session
Monday, November 16, 2026
8:15 AM - 8:45 AM
Grand Ballroom
Industry Breakfast Symposium (Non-CME)
9:00 AM - 10:35 AM
Grand Ballroom
Amyloidosis – Making the Diagnosis
Moderators:
Eloisa Riva (Uruguay) & Stefan Schönland (Germany)
9:00 AM - 9:10 AM
Suspecting Amyloidosis – Amyloid vs Amyloidosis: Could We Ever Be Too Early?
Speaker:
Frederick Ruberg (USA)
9:10 AM - 9:20 AM
Getting the Sample – Which Tissue to Target?
Speaker:
Paolo Milani (Italy)
9:20 AM - 9:40 AM
Tissue Diagnosis - From Congo Red Staining to Immunohistochemistry and Mass Spec
Speaker:
Hironobu Naiki (Japan)
9:40 AM - 9:55 AM
Q&A
10:05 AM - 10:15 AM
Artificial Intelligence-Based Recognition of Light Chain Amyloidosis Among Patients With MGUS and Smoldering Multiple Myeloma (#002)
Speaker:
Eli Muchtar (Israel)
10:15 AM - 10:25 AM
Refining the AL Amyloidosis International Staging System (AL-ISS) With Left Ventricular Ejection Fraction – An Independent Incremental Prognostic Marker (#003)
Speaker:
Jahanzaib Khwaja (United Kingdom)
10:25 AM - 10:35 AM
Comprehensive Approach to Safely Defer Endomyocardial Biopsy in Transthyretin Amyloid Cardiomyopathy with Monoclonal Protein Abnormalities: A Multicenter Study (#004)
Speaker:
Bilal Ansari (USA)
10:35 AM - 11:00 AM
Exhibition Room + Florida Room
Coffee Break and Poster Viewing
10:35 AM - 11:00 AM
Florida Room - Poster Station 1
E-poster Session 1 - Treatments of AL
Moderator:
Angela Dispenzieri (USA)
10:35 AM - 10:39 AM
Phase 1/2 Dose Escalation and Expansion Study of Etentamig in Patients With Relapsed or Refractory Light Chain Amyloidosis (#045)
Speaker:
Vaishali Sanchorawala (USA)
10:39 AM - 10:43 AM
PROT-001, A First-In-Class Lambda Light Chain Kinetic Stabilizer for AL Amyloidosis: Results from the Phase I PRO-1A-101 Study (#046)
Speaker:
Mike Petrassi (USA)
10:43 AM - 10:47 AM
Daratumumab Combined with Venetoclax and Dexamethasone as First‑Line Treatment for t(11;14) Light‑Chain Amyloidosis: Preliminary Results of a Phase II Prospective, Single‑Arm Study (#047)
Speaker:
Kaini Shen (China)
10:47 AM - 10:51 AM
Early dFLC Response Guided Therapy for t(11;14) AL Amyloidosis: A Multi-Center Prospective Study (#048)
Speaker:
Yang Liu (China)
10:51 AM - 10:55 AM
Characterization of Fc-Peptide Fusion Peptibodies to Serve as Opsonins for Macrophage-Mediated Clearance of Amyloid Deposits (#049)
Speaker:
Trevor Hancock (USA)
10:55 AM - 10:59 AM
Early Anti-BCMA CAR-T as a Response-Deepening Strategy in AL Amyloidosis With Insufficient Response to Frontline Therapy (#050)
Speaker:
Eyal Lebel (Israel)
10:35 AM - 11:00 AM
Florida Room - Poster Station 2
E-poster Session 2 - Treatments of ATTR
Moderator:
Giovanni Palladini (Italy)
10:35 AM - 10:39 AM
Acoramidis Reduces Days Lost to Death and/or Cardiovascular-Related Hospitalization, Preserving Time Alive Outside the Hospital in Patients With Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM (#051)
Speaker:
Richard Wright (USA)
10:39 AM - 10:43 AM
Efficacy and Safety of Eplontersen in Patients With Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy (Attr-CM): Results From the CARDIO-TTRansform Study (#052)
Speaker:
Marcia Waddington (Brazil)
10:43 AM - 10:47 AM
Long-Term Effects of Acoramidis on Mortality in Variant Transthyretin Amyloid Cardiomyopathy, Including p.Val142Ile: Findings From the Open-Label Extension of ATTRibute-CM (#053)
Speaker:
Frederick L. Ruberg (USA)
10:47 AM - 10:51 AM
Sacubitril/Valsartan in ATTR-CM Patients With Heart Failure and Reduced Systolic Function Receiving Tafamidis: Results From the Attracking Spanish Registry (#054)
Speaker:
Rafael Martin-Portugues (Spain)
10:51 AM - 10:55 AM
eGFR Dips After Acoramidis Initiation Are Associated With Clinical Benefits in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings From the ATTRibute-CM Trial (#055)
Speaker:
Daniel P. Judge (USA)
10:55 AM - 10:59 AM
Protective Effect of Acoramidis on Kidney Function in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings From ATTRibute-CM and its Open-Label Extension Study (#056)
Speaker:
Daniel P. Judge (USA)
11:00 AM - 12:35 PM
Grand Ballroom
Amyloidosis – Assessing Organ Involvement
Moderators:
Erika Brulc (Argentina) & Maria Picken (USA)
11:00 AM - 11:10 AM
Cardiac Work Up
Speaker:
Pablo Garcia-Pavia (Spain)
11:10 AM - 11:20 AM
Neurological Work Up
Speaker:
Marcia Waddington (Brazil)
11:20 AM - 11:30 AM
Novel Imaging Techniques in Amyloidosis
Speaker:
Sharmila Dorbala (USA)
11:30 AM - 11:45 AM
Q&A
11:45 AM - 11:55 AM
An AI-ECG Model Predicts All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy (#005)
Speaker:
Mariana Brandão (Spain)
11:55 AM - 12:05 PM
¹²⁴I-evuzamitide PET/CT for the Diagnosis of Cardiac Amyloidosis: Primary Results of a Prospective Multicenter Study (#006)
Speaker:
Sharmila Dorbala (USA)
12:05 PM - 12:15 PM
Cardiac Time-Harmonic Elastography (THE) for Non-invasive Myocardial Stiffness Quantification Across the Full Spectrum of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (#007)
Speaker:
Brunhilde Wellge (Germany)
12:15 PM - 12:25 PM
Myocardial Fibroblast Activation in Cardiac Amyloidosis: A Prospective Pilot Study Using 18F-FAPI-74 PET/CT (#008)
Speaker:
Chaitanya Rojulpote (USA)
12:25 PM - 12:35 PM
Positron Emission Tomography With I-124-Evuzamitide Identifies Cardiac and Extra-Cardiac Organ Involvement in Various Types of Systemic Amyloidosis (#009)
Speaker:
Nirija Ranjit Anderson (United Kingdom)
12:35 PM - 1:00 PM
Foyer
Lunch Pickup
2:00 PM - 3:30 PM
Grand Ballroom
Basic Research in Amyloidosis
Moderators:
Lorena Saelices Gomez (USA) & Christophe Sirac (France)
2:00 PM - 2:15 PM
Bench to Bedside – Translating the Findings to Clinic
Speaker:
Jeffery Kelly (USA)
2:15 PM - 2:30 PM
Proteomics-unraveling the Mechanisms in Amyloidosis
Speaker:
Francesca Lavatelli (Italy)
2:30 PM - 2:40 PM
Q&A
2:40 PM - 2:50 PM
Beyond Amyloid: Plasma Proteomics Uncovers Immunofibrotic and Vascular Remodeling in Transthyretin Amyloidosis (#010)
Speaker:
Inés Losada (Spain)
2:50 PM - 3:00 PM
The V122I Mutation Alters the Supramolecular Geometry of ATTR Fibrils While Preserving the Amyloid Fold (#011)
Speaker:
Maria del Carmen Fernandez Ramirez (USA)
3:00 PM - 3:10 PM
Development of Neutrophil Activating Immunotherapeutics to Induce Amyloid Dissolution (#012)
Speaker:
Joseph Jackson (USA)
3:10 PM - 3:20 PM
Mouse Models of AL: NOD SCID γ Mice and AL Light-chain Producing CHO Cells (#013)
Speaker:
Colin Kloock (USA)
3:20 PM - 3:30 PM
Meta-Analysis of Genome-wide Association Studies Identifies Novel Genetic Determinants of Plasma Transthyretin Concentration (#014)
Speaker:
Mette Christoffersen (Denmark)
3:30 PM - 4:00 PM
Exhibition Room + Florida Room
Coffee Break and Poster Viewing
3:30 PM - 4:00 PM
Florida Room - Poster Station 1
E-poster Session 3 - Basic Science ATTR
Moderator:
Alexander Carpinteiro (Germany)
3:30 PM - 3:34 PM
Extracellular Vesicle Proteomics Reveals a Plasminogen-Centered Molecular Signature in Transthyretin Cardiac Amyloidosis (#057)
Speaker:
zaroui amira (France)
3:34 PM - 3:38 PM
Naturally-Occurring Antibodies Targeting Transthyretin in ATTR Cardiomyopathy (#058)
Speaker:
Stephan Settelmeier (Germany)
3:38 PM - 3:42 PM
Proteostasis is Disrupted in Human Endothelial Cells by Serum From ATTR Patients and is Rescued by Tafamidis Treatment (#059)
Speaker:
Despoina D. Gianniou (Greece)
3:42 PM - 3:46 PM
In Vivo Evidence of Ongoing Cardiac Damage and Sympathetic Activation in Patients With Cardiac Amyloidosis (#060)
Speaker:
Vincenzo Castiglione (Italy)
3:46 PM - 3:50 PM
Suboptimal LDL Cholesterol Target Achievement in Cardiac ATTR Amyloidosis Despite Disease-modifying Therapy (#061)
Speaker:
Gina Barzen (Germany)
3:50 PM - 3:54 PM
Development of a New Advanced Platform for Personalized Treatment of Transthyretin Amyloid Cardiomyopathy (#062)
Speaker:
Olalla Iglesias García (Spain)
3:54 PM - 3:58 PM
Identification of Genetic Risk Variants for Cardiac wtATTR Amyloidosis: From Clinical Surrogate Markers to Genome-Wide Analysis in the UK Biobank (#063)
Speaker:
Teresa Trenkwalder (Germany)
3:30 PM - 4:00 PM
Florida Room - Poster Station 2
E-poster Session 4 - Prognosis/Natural History Other More Rare Amyloidoses
Moderator:
Anita D’Souza (USA)
3:30 PM - 3:34 PM
Clinical Spectrum and Stages of AIL1RAP in Neonatal-Onset Multisystem Inflammatory Disease (NOMID) (#064)
Speaker:
Sara Alehashemi (USA)
3:34 PM - 3:38 PM
Exploring AL Amyloidosis by Underlying Clone: B-Cell Versus Plasma Cell in a Population-Based Registry (#065)
Speaker:
Flores Weverling (Netherlands)
3:38 PM - 3:42 PM
In AA amyloidosis NT-proBNP is Significantly Correlated With CKD Stage Rather Than Cardiac Involvement (#066)
Speaker:
Helen Lachmann (United Kingdom)
3:42 PM - 3:46 PM
AA Amyloidosis in a Large National Cohort of 454 Patients: Etiologies, Renal Involvement and Survival (#067)
Speaker:
Sophie GEORGIN-LAVIALLE (France)
3:46 PM - 3:50 PM
Hereditary lysozyme (ALys) amyloidosis: Clinical Characteristics and Outcome in a Single-Center Series of 48 Cases (#068)
Speaker:
Mario Nuvolone (Italy)
3:50 PM - 3:54 PM
Childhood Onset, Indolent Progression, and Risk of Hepatic Rupture: The Natural History of Hereditary Lysozyme Amyloidosis (#069)
Speaker:
Jack Carruthers (United Kingdom)
3:54 PM - 3:58 PM
Impact of Diagnostic Delay on Outcomes in AA Amyloidosis (#070)
Speaker:
Marco Basset (Italy)
3:30 PM - 4:00 PM
Conference Room
Industry Product Theatre (Non-CME)
4:00 PM - 6:00 PM
Grand Ballroom
Current Approaches to Treatment
Moderators:
Peter Mollee (Australia) & Vaishali Sanchorawala (USA)
4:00 PM - 4:10 PM
First Line Therapy: What Are The Options
Speaker:
Efstathios Kastritis (Greece)
4:10 PM - 4:20 PM
Challenges in Identifying and Treating Disease Progression
Speaker:
Eli Muchtar (Israel)
4:20 PM - 4:30 PM
Novel Therapeutic Options
Speaker:
Giada Bianchi (USA)
4:30 PM - 4:40 PM
ASCT: Do We Still Need Autologous Stem Cell Transplant in AL?
Speaker:
Heather Landau (USA)
4:40 PM - 5:00 PM
Q&A
5:00 PM - 5:10 PM
Clinical Patterns and Outcomes of AL Amyloid Recurrence Post-Kidney Transplantation (#015)
Speaker:
Abdullah Jalal (USA)
5:10 PM - 5:20 PM
Updated Efficacy and Safety of Linvoseltamab (LINVO) Monotherapy in Patients With Relapsed or Refractory (RR) Systemic Light Chain (AL) Amyloidosis: Phase 1/2 LINKER-AL2 (#016)
Speaker:
Ashutosh Wechalekar (United Kingdom)
5:20 PM - 5:30 PM
Deep M-Seq: an NGS-based Approach for Personalized MRD Detection in Monoclonal Gammopathies (#017)
Speaker:
Francesca Lattarulo (Italy)
5:30 PM - 5:40 PM
Curability in Immunoglobulin Light Chain (AL) Amyloidosis (#018)
Speaker:
Meletios-Athanasios Dimopoulos (Greece)
5:40 PM - 5:50 PM
Anti-fibril Antibodies for Systemic Amyloidosis Treatment (#019)
Speaker:
Jack Wade (United Kingdom)
5:50 PM - 6:00 PM
TeclistAMY (EMN40): A Phase 2 Trial of Teclistamab in Patients With Previously Treated Light-chain (AL) Amyloidosis (#020)
Speaker:
Murielle Roussel (France)
6:00 PM - 6:45 PM
Florida Room - Poster Station 1
E-poster Session 5 - Diagnosis AL
Moderator:
Heather Landau (USA)
6:00 PM - 6:04 PM
Single Domain Antibodies Targeting a Common Fibrillar Epitope in Al Amyloidosis (#071)
Speaker:
Alessio Lampis (France)
6:04 PM - 6:08 PM
Blood M-Seq for Bone Marrow-Free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies (#072)
Speaker:
Alice Nevone (Italy)
6:08 PM - 6:12 PM
Light Chain Fragmentation in Patients with Monoclonal Gammopathies (#073)
Speaker:
David Murray (USA)
6:12 PM - 6:16 PM
Delayed Diagnosis of Immunoglobulin Light Chain AL Amyloidosis in Patients With Pre-existing MGUS: A Persistent Clinical Challenge (#074)
Speaker:
Claudia Bellofiore (Italy)
6:16 PM - 6:20 PM
Diagnostic Challenges and Treatment Patterns in Systemic AL Amyloidosis: Results From the First Nationwide Brazilian Multicenter Registry (#075)
Speaker:
Pedro Garibaldi (Brazil)
6:20 PM - 6:24 PM
Quantitative ¹²⁴I-evuzamitide PET/CT for Diagnosis of Cardiac Amyloidosis (#076)
Speaker:
Sharmila Dorbala (USA)
6:24 PM - 6:28 PM
Fibroscan and GGT for Detecting Hepatic Involvement in AL Amyloidosis (#077)
Speaker:
Sorina Nicoleta Badelita (Romania)
6:28 PM - 6:32 PM
Pre-Diagnostic Cardiac Biomarker Trajectories in AL Versus ATTR Amyloidosis: A Multi-Institutional Real-World Analysis (#078)
Speaker:
Grace Ferri (USA)
6:32 PM - 6:36 PM
Cystatin C‒ Versus Creatinine-Based eGFR Reclassifies One-Third of Patients With AL Amyloidosis Across Clinical Decision Thresholds (#079)
Speaker:
Andrew Staron (USA)
6:36 PM - 6:40 PM
Disease Profiles and Clinical Course of the 3 Main Types of Systemic Amyloidosis With Cardiac Involvement (#080)
Speaker:
Paolo Milani (Italy)
6:40 PM - 6:44 PM
Mechanistic Insights Into AL and ATTR Cardiac Amyloidosis Through Wide-Range Plasma Proteomics (#081)
Speaker:
Olivier Clerc (USA)
6:00 PM - 6:45 PM
Florida Room - Poster Station 2
E-poster Session 6 - Disease Outcomes
Moderator:
Ashutosh Wechalekar (United Kingdom)
6:00 PM - 6:04 PM
Disease-Modifying Therapies and All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (#082)
Speaker:
Hamza Naveed (USA)
6:04 PM - 6:08 PM
Subcutaneous Fat Proteomics Reveals Systemic Amyloid Biology and Prognostic Signatures (#083)
Speaker:
Melinda Tan (Singapore)
6:08 PM - 6:12 PM
Renal Outcomes in Hereditary Fibrinogen a Alpha-Chain Amyloidosis (#084)
Speaker:
Jack Carruthers (United Kingdom)
6:12 PM - 6:16 PM
Renal Involvement in Late-Onset Hereditary Transthyretin Amyloidosis: Findings From a Large Swedish Cohort (#085)
Speaker:
Intissar Anan (Sweden)
6:16 PM - 6:20 PM
Improving Awareness and Early Recognition of ATTR-CM Through a National Educational Initiative (#086)
Speaker:
John Dawod (Kenya)
6:20 PM - 6:24 PM
Clinical Settings and Histopathological Diversity of Kidney Involvement in Hereditary Transthyretin Amyloidosis (#087)
Speaker:
Ana Cunha (Portugal)
6:24 PM - 6:28 PM
Solid Organ Transplantation in Systemic Amyloidosis: A 60-Year Experience Across 264 Recipients (#088)
Speaker:
Andrew Staron (USA)
6:28 PM - 6:32 PM
Long-Term Clinical Outcomes of Acquired Transthyretin Amyloidosis After Domino Liver Transplantation: A Single-Center Longitudinal Study (#089)
Speaker:
Yohei Misumi (Japan)
6:32 PM - 6:36 PM
Anakinra Treatment Real World Evidence in AA Amyloidosis: A Retrospective Study on 51 Patients and Literature Review (#090)
Speaker:
Sophie GEORGIN-LAVIALLE (France)
6:36 PM - 6:40 PM
The Critical Importance of Preserving Hand Function in ATTRv-PN: Insights Inspired by the Multiple Sclerosis ThinkHand Framework (#091)
Speaker:
Marco Luigetti (Italy)
6:00 PM - 7:30 PM
Exhibition Room + Florida Room
Poster Viewing Session
6:45 PM - 7:30 PM
Florida Room - Poster Station 1
E-poster Session 7 - Translational
Moderator:
Kevin Alexander (USA)
6:45 PM - 6:49 PM
Development of TTRACK Study Diagnostic Scores to Identify Elevated Risk of Transthyretin Amyloid Cardiomyopathy in Older Patients With Unexplained Hypertrophic Cardiomyopathy (#092)
Speaker:
Thibaud Damy (France)
6:49 PM - 6:53 PM
Development of Rabbit Monoclonal Antibodies for the Accurate Typing Diagnosis of Systemic Amyloidosis (#093)
Speaker:
Kai Miyazaki (Japan)
6:53 PM - 6:57 PM
Affibody Molecules as Molecular Shield Against β2-Microglobulin Aggregation Under Lysosomal-like Conditions (#094)
Speaker:
Cristina Visentin (Italy)
6:57 PM - 7:01 PM
LMD-MS and Immunoelectron Microscopy for Amyloid Typing: Prospective Clinical Evaluation (#095)
Speaker:
Hans Christian Beck (Denmark)
7:01 PM - 7:05 PM
Structural Determinants of β2-Microglobulin Aggregation and Their Impact on NLRP3 Inflammasome Activation in Multiple Myeloma (#096)
Speaker:
Cristina Visentin (Italy)
7:05 PM - 7:09 PM
Analysis of Cell Free DNA in Monoclonal Gammopathy of Renal Significance Reveals Rare Somatic Variants and Candidate Driver Mutations (#097)
Speaker:
Louis Williams (USA)
7:09 PM - 7:13 PM
Red-Flag Diagnostic Claims Patterns Preceding Light Chain Amyloidosis in Patients With Monoclonal Gammopathy: A Longitudinal Study (#098)
Speaker:
Anita DSouza (USA)
7:17 PM - 7:21 PM
Comparison of MRD Quantification by Multiparametric Flow Cytometry vs Dual Cyclin D1/CD138 Immunohistochemistry in Cyclin D1-Positive AL Amyloidosis (#100)
Speaker:
Eric Burks (USA)
7:21 PM - 7:25 PM
Clinical-Histopathological Profile of Biopsy-Diagnosed Renal Amyloidosis in Brazil: Analysis of Multicenter Cohort of 364 Cases (#101)
Speaker:
Stanley Araujo (Brazil)
6:45 PM - 7:30 PM
Florida Room - Poster Station 2
E-poster Session 8 - Prognosis AL
Moderator:
Sharmila Dorbala (USA)
6:45 PM - 6:49 PM
Mortality Risk Among Patients With Cardiogenic Shock Due to Light-Chain Amyloidosis (#102)
Speaker:
Spencer Carter (USA)
6:49 PM - 6:53 PM
IGKV1-33 Germline Gene Usage Identifies a High-Risk Subgroup with Cardiomyocyte Damage and Inferior Survival in Kappa AL Amyloidosis (#103)
Speaker:
Mario Nuvolone (Italy)
6:53 PM - 6:57 PM
A Multicenter Analysis of Kappa vs. Lambda AL Amyloidosis (#104)
Speaker:
Sara Oubari (Germany)
6:57 PM - 7:01 PM
Improved Survival in Systemic AL Amyloidosis: 25-Year Analysis of Outcomes and Clinical Determinants (#105)
Speaker:
Maximilian Steinhardt (USA)
7:01 PM - 7:05 PM
Twelve-Month Proteinuria Response, eGFR Status, and Subsequent Renal Outcomes in AL Amyloidosis (#106)
Speaker:
Eli Muchtar (Israel)
7:05 PM - 7:09 PM
Integrated Multi-Omics Analysis in AL Amyloidosis Identifies Proteomic Signatures Associated With Survival (#107)
Speaker:
Julie Courraud (Greece)
7:09 PM - 7:13 PM
Isotype Matters? An International Dual-Cohort Study Comparing Kappa and Lambda AL Amyloidosis Outcomes (#108)
Speaker:
Giovanni Palladini (Italy)
7:13 PM - 7:17 PM
Measurable Residual Disease Negativity is Associated With Superior Renal Response Depth in AL Amyloidosis (#109)
Speaker:
Alec Seidman Sorsby (USA)
7:17 PM - 7:21 PM
Overall Survival Before and After Daratumumab Approval in Systemic AL Amyloidosis: A Prospective Nationwide Registry Study (#110)
Speaker:
Sena Akyüz (Germany)
7:21 PM - 7:25 PM
Machine Learning–Based Analysis of Organ Recovery in Patients With AL Amyloidosis (#111)
Speaker:
Afua Ofori-Darko (USA)
7:25 PM - 7:29 PM
Comparative Outcomes of AL Amyloidosis and Multiple Myeloma in the Era of Modern Therapies (#112)
Speaker:
Paolo Milani (Italy)
Tuesday, November 17, 2026
9:00 AM - 11:00 AM
Grand Ballroom
TTR
Moderators:
Thibaud Damy (France) & Masahide Yazaki (Japan)
9:00 AM - 9:10 AM
ATTR: Pitfalls and Common Mistakes with Diagnosis
Speaker:
Faizi Jamal (USA)
9:10 AM - 9:20 AM
Current Management of ATTR Cardiac Amyloidosis
Speaker:
Fabio Fernandes (Brazil)
9:20 AM - 9:30 AM
Assessment of Renal Involvement in ATTR
Speaker:
Luisa Lobato (Portugal)
9:30 AM - 9:40 AM
CNS Manifestations of ATTR Amyloidosis: The Most Serious and Common Complications in Long-Lived Patients
Speaker:
Yoshiki Sekijima (Japan)
9:40 AM - 10:00 AM
Q&A
10:00 AM - 10:10 AM
Circulating Transthyretin Fragments Differ Between Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy and Controls (#021)
Speaker:
Sie Kronborg Fensman (Denmark)
10:10 AM - 10:20 AM
Transthyretin Amyloid Fibrils Adopt Distinct Folds in the Brain (#022)
Speaker:
Lorena Saelices (USA)
10:20 AM - 10:30 AM
AI-ECG as a Marker of Disease Progression in Transthyretin Amyloid Cardiomyopathy (#023)
Speaker:
Mariana Brandão (Spain)
10:30 AM - 10:40 AM
Predictors of Phenoconversion in V50M Hereditary Transthyretin Amyloidosis: Distinguishing Long-Term Risk from Imminent Disease Onset (#024)
Speaker:
Isabel Maria Santos Conceicao (Portugal)
10:40 AM - 10:50 AM
External Quality Assessment Scheme for Genetic Testing in Hereditary Amyloidosis: Evaluation of Reporting Standards Across International Laboratories Between 2024–2026 (#025)
Speaker:
Dorota Rowczenio (United Kingdom)
10:50 AM - 11:00 AM
Histological Regression of Amyloid During Patisiran Treatment (#026)
Speaker:
Inge Strating (Netherlands)
11:00 AM - 12:00 PM
Exhibition Room + Florida Room
Coffee Break and Poster Viewing
11:00 AM - 12:00 PM
Florida Room - Poster Station 1
E-poster Session 9 - Prognosis ATTR
Moderator:
Mathew Maurer (USA)
11:00 AM - 11:04 AM
Cardiac Sympathetic Dysfunction Assessed by 123I-MIBG Imaging is Associated With Ventricular Arrhythmias in Wild-type Transthyretin Amyloid Cardiomyopathy: Insights From the iNERVE Study (#113)
Speaker:
Denise Cristiana Faro (Netherlands)
11:04 AM - 11:08 AM
Establishing an International Registry for ATTR Amyloidosis: Current Status of Center Activation and Future Perspectives (#114)
Speaker:
Paolo Milani (Italy)
11:08 AM - 11:12 AM
Deep Phenotyping Uncovers Diagnostic Blind Spots In ATTRV30M Amyloidosis: Insights into Biomarker Dissociation (#115)
Speaker:
Jose Pedro Escaleira (Portugal)
11:12 AM - 11:16 AM
Serum Transthyretin to NT-proBNP Ratio as a Novel Prognostic Measure in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial (#116)
Speaker:
Hanna K. Gaggin (USA)
11:16 AM - 11:20 AM
ACO-REAL: Baseline Characteristics and Treatment Patterns of Acoramidis in Real-World Patients With ATTR-CM From Italy (Phase 4, Interim Results) (#117)
Speaker:
Francesco Cappelli (Italy)
11:20 AM - 11:24 AM
Anemia and Renal Dysfunction: An Overlooked Prognostic Link in Cardiac Amyloidosis (#118)
Speaker:
Pedro Passaglia (Brazil)
11:24 AM - 11:28 AM
Early Markers of Disease Progression in Patients With Transthyretin Cardiac Amyloidosis (#119)
Speaker:
Clea González-Maniega (Spain)
11:28 AM - 11:32 AM
Relative Importance of Markers of Progression in Patients With Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Post-hoc Analysis (#120)
Speaker:
Pablo Garcia-Pavia (Spain)
11:32 AM - 11:36 AM
Outcomes in Transthyretin Amyloidosis According to Cardiac Implantable Electronic Device Status: A Nationwide Cohort (#121)
Speaker:
Vincent ALGALARRONDO (France)
11:36 AM - 11:40 AM
Six-Month Transthyretin Response Identifies Early Treatment Efficacy in Wild-Type Transthyretin Cardiac Amyloidosis Treated With Tafamidis (#122)
Speaker:
Paolo Milani (Italy)
11:40 AM - 11:44 AM
Mortality in Octagenarian Patients With Transthyretin Amyloidosis Treated With Tafamidis. A Systematic Review and Metanalysis (#123)
Speaker:
Christiane Santo (Brazil)
11:44 AM - 11:48 AM
Longitudinal QRS Voltage Decline Outperforms Structural Echocardiography for Prognostic Stratification in Transthyretin Cardiac Amyloidosis (#124)
Speaker:
Marina Santos (Brazil)
11:48 AM - 11:52 AM
GDF-15 as a Potential Marker of Disease Progression and Multisystem Involvement in Patients With TTR Amyloidosis (#125)
Speaker:
Angeliki Alifragki (Greece)
11:52 AM - 11:56 AM
Decline in Short Physical Performance Battery on Follow-up Testing is Associated with Recurrent Heart Failure Hospitalization in Transthyretin Amyloid Cardiomyopathy (#126)
Speaker:
Bilal Ansari (USA)
11:00 AM - 12:00 PM
Florida Room - Poster Station 2
E-poster Session 10 - Basic Science AL + Other More Rare Amyloidoses
Moderator:
Efstathios Kastritis (Greece)
11:00 AM - 11:04 AM
Multiorgan Structural Characterization of AA Amyloids From a Diseased Cat Reveals Deposition of Highly Heterogeneous Pathological Fibrils (#127)
Speaker:
Stefano Ricagno (Italy)
11:04 AM - 11:08 AM
AmyLiteDx: A Mass Spectrometry-Based Platform for Sensitive and In-Depth Analysis of Amyloidogenic Immunoglobulin Light Chains in AL Amyloidosis (#128)
Speaker:
Mike Petrassi (USA)
11:08 AM - 11:12 AM
N-Glycosylation Multifaceted Effect on κ-Light Chains Associated With AL Amyloidosis (#129)
Speaker:
Sarita Puri (India)
11:12 AM - 11:16 AM
Time Course of Cardiac Dysfunction in an AApoA2 Mouse Model (#130)
Speaker:
Clement Corruble (France)
11:16 AM - 11:20 AM
Small Molecule Stabilization of Diverse Amyloidogenic Immunoglobulin Light Chains Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry (#131)
Speaker:
Gareth Morgan (USA)
11:20 AM - 11:24 AM
Anselamimab Targets Cytotoxic Soluble Prefibrillar Species and Insoluble Fibrils in Light Chain Amyloidosis (#132)
Speaker:
Scott Swenson (USA)
11:24 AM - 11:28 AM
CryoEM Expands the Structural Repertoire of Tissue-Extracted Lambda-6 Light Chain Amyloids (#133)
Speaker:
Noorul Huda (USA)
11:28 AM - 11:32 AM
Cryo-EM Analysis of Patient-Derived Amyloid Fibrils Reveals Structural Diversity Across Systemic Amyloidoses (#134)
Speaker:
Lorena Saelices (USA)
11:32 AM - 11:36 AM
PROT-001 Suppresses Amyloidogenic Light Chain Induced BNP Signaling and Cardiotoxicity in Human Cardiomyocytes (#135)
Speaker:
Mike Petrassi (USA)
11:36 AM - 11:40 AM
Nanobodies Targeting and Neutralizing Cardiotoxic Immunoglobulin Light Chains as Novel Therapeutic Strategy for AL Amyloidosis Patients (#136)
Speaker:
Stefano Ricagno (Italy)
11:40 AM - 11:44 AM
Structural and Functional Characterization of ApoA-IV Variants Associated With Medullary Amyloidosis (#137)
Speaker:
Ales Hnizda (Czech Republic)
11:44 AM - 11:48 AM
PROT-001 Demonstrates Compatibility with Bortezomib-Based Regimens While Preserving Plasma Cell Cytotoxicity (#138)
Speaker:
Mike Petrassi (USA)
11:48 AM - 11:52 AM
Compartment-Resolved Proteomics Defines Tissue-Wide Injury Programs in Renal AL Amyloidosis (#139)
Speaker:
Kenneth Jin Chang Lim (USA)
11:52 AM - 11:56 AM
Structural Characterization of Atrial Natriuretic Peptide Amyloid Fibrils From Isolated Atrial Amyloidosis Patients (#140)
Speaker:
Stefano Ricagno (Italy)
12:00 PM - 12:30 PM
Foyer
Lunch Pickup
12:00 PM - 1:30 PM
Exhibition Room + Florida Room
Lunch
12:30 PM - 1:30 PM
Grand Ballroom
Industry Sponsored Lunch Symposium (Non-CME)
1:30 PM - 3:00 PM
Grand Ballroom
Combined Therapies / Antibodies / Depleters
Moderators:
Martha Grogan (USA) & Markus Weiler (Germany)
1:30 PM - 1:40 PM
When is it Time to Change Treatment in ATTRwt and ATTRv?
Speaker:
Violaine Plante-Bordeneuve (France)
1:40 PM - 1:50 PM
Defining Treatment Response and Disease Progression in ATTR
Speaker:
Mitsuharu Ueda (Japan)
1:50 PM - 2:00 PM
Future Therapies - Combined therapies
Speaker:
Mathew Maurer (USA)
2:00 PM - 2:20 PM
Q&A
2:20 PM - 2:30 PM
Impact of Lifetime Physical Activity and Post-Diagnosis Exercise on Clinical Trajectories and Functional Preservation in Wild-Type Transthyretin Amyloidosis on Tafamidis Therapy (#027)
Speaker:
Michela Giovanna Coccia (Italy)
2:30 PM - 2:40 PM
Use of Vericiguat in Patients With Cardiac Amyloidosis: A Case Series (#028)
Speaker:
Clarissa Carmona de A. Bellagamba (Italy)
2:40 PM - 2:50 PM
Outcomes of Early Stage ATTR-CM Treated With Tafamidis: Real-World Results From the Attracking Spanish Registry (#029)
Speaker:
Rafael Martin-Portugues (Spain)
2:50 PM - 3:00 PM
ACO-REAL: Real-world Use of Acoramidis in People With ATTR-CM in Belgium, by Prior Treatment Status (Phase 4, Interim Results) (#030)
Speaker:
Karl Dujardin (Belgium)
3:00 PM - 3:30 PM
Exhibition Room + Florida Room
Coffee Break and Poster Viewing
3:00 PM - 3:30 PM
Florida Room - Poster Station 1
E-poster Session 11 - Diagnosis ATTRv
Moderator:
Nelson Leung (USA)
3:00 PM - 3:04 PM
Adverse Outcomes of TTR p.V142I Carriers With Non-amyloid Heart Failure: The SCAN-MP Study (#141)
Speaker:
Frederick Ruberg (USA)
3:04 PM - 3:08 PM
Use of Point-of-Care Ultrasound (POCUS) to Measure Post-Voiding Residual Urine in Patients with Hereditary Transthyretin Amyloidosis (#142)
Speaker:
Carlos Perez Gomes (Brazil)
3:08 PM - 3:12 PM
Cardio-Specific miRNA as a Possible Biomarker in Transthyretin-Related Hereditary Amyloidosis (#143)
Speaker:
Marco Ceccanti (Italy)
3:12 PM - 3:16 PM
Disrupted Glutathione Homeostasis in ATTRV50M Pathogenesis (#144)
Speaker:
Gabriella Johannson (Sweden)
3:16 PM - 3:20 PM
Severe Dysautonomia Mirrors Cardiac Structural Damage in ATTRv Val142Ile Cardiomyopathy (#145)
Speaker:
BRUNO BUENO (Brazil)
3:20 PM - 3:24 PM
Hidden Disease: Uncovering Autonomic Failure in Asymptomatic Val142Ile Carriers With Normal Echocardiograms (#146)
Speaker:
BRUNO BUENO (Brazil)
3:24 PM - 3:28 PM
Quantitative MR Neurography Reveals Distinct Imaging Patterns in Amyloid and Other Diffuse Neuropathies (#147)
Speaker:
Jennifer Hayes (USA)
3:00 PM - 3:30 PM
Florida Room - Poster Station 2
E-poster Session 12 - Imaging + AI/Electronic Records to Facilitate Diagnosis
Moderator:
Martha Grogan (USA)
3:00 PM - 3:04 PM
A Validated Transthyretin Amyloid Cardiomyopathy (ATTR-CM) United States (US) Claims-Based Coding Algorithm (ValidATTR-US) (#148)
Speaker:
John Isaiah Jimenez (USA)
3:04 PM - 3:08 PM
Extracardiac Uptake of the SPECT/CT Imaging Agent, 99mTc-p5+14 (AT-05), in Patients With AL or ATTR Cardiac Amyloidosis (#149)
Speaker:
Emily Martin (USA)
3:08 PM - 3:12 PM
Automated Extraction of Cardiovascular Comorbidities From EPIC Notes for an Amyloidosis Registry (#150)
Speaker:
Ethan Hortelano (USA)
3:12 PM - 3:16 PM
Diagnostic Yield of Cardiac Amyloid Radionuclide Imaging for Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome and Lumbar Spinal Stenosis: A Systematic Review and Meta-Analysis (#151)
Speaker:
Mathew Maurer (USA)
3:16 PM - 3:20 PM
Should Interventricular Septal Thickness Be Indexed in Cardiac Amyloidosis? Implications for Sex-Specific Diagnostic Thresholds (#152)
Speaker:
María García de Pedro (Spain)
3:20 PM - 3:24 PM
Early Small Fiber Involvement in Hereditary Transthyretin Amyloidosis: A Multimodal Study Combining ¹²³I-mIBG, Skin Biopsy, and Neurophysiology (#153)
Speaker:
Marco Ceccanti (Italy)
3:24 PM - 3:28 PM
Left Ventricular Diastolic Filling Characteristics in Wild-Type Transthyretin Amyloid Cardiomyopathy by Simultaneous Echocardiographic and Invasive Hemodynamic Assessment (#154)
Speaker:
Thomas Weiss (Denmark)
3:30 PM - 4:30 PM
Grand Ballroom
When Should We Start Treatment? – Impact of Screening
Moderators:
Alexander Carpinteiro (Germany) & Maite Cibeira (Spain)
3:30 PM - 3:40 PM
Genetic Counseling/Testing
Speaker:
Laura Obici (Italy)
3:40 PM - 3:50 PM
Preventive Therapies – What is the Ideal Time to Start Treatment
Speaker:
Alejandra Gonzalez-Duarte (Mexico)
3:50 PM - 4:00 PM
Q&A
4:00 PM - 4:10 PM
Results of A Randomized Prospective Trial Using Artificial Intelligence Enhanced ECG and Other Models to Diagnose Cardiac Amyloidosis (PREDICT-AMY TRIAL) (#031)
Speaker:
Angela Dispenzieri (USA)
4:10 PM - 4:20 PM
Structure-Guided Detection of Circulating Transthyretin Aggregates for Early Diagnosis and Monitoring of ATTR Amyloidosis (#032)
Speaker:
Lorena Saelices (USA)
4:20 PM - 4:30 PM
Implementation and Accuracy of a Novel Screening Algorithm, Embedded Into the Greek National Prescription Service, Towards the Detection of Patients With Transthyretin Amyloidosis. Study Design and Preliminary Findings (#033)
Speaker:
Kimon Stamatelopoulos (Greece)
4:30 PM - 5:00 PM
Grand Ballroom
Patient Perspective Round Table
Moderator:
Anita D’Souza (USA)
Speakers:
Giovanni D’Alessio (Italy), Bob Gibson (USA) & Isabelle Lousada (USA)
5:00 PM - 6:00 PM
Grand Ballroom
Challenging Cases Discussed by Experts
Speakers:
Morie Gertz (USA), Seung-Pyo Lee (Korea), Giovanni Palladini (Italy) & Phillip Scheinberg (Brazil)
7:00 PM - 10:00 PM
Special Session (Non-CME)
Wednesday, November 18, 2026
8:00 AM - 9:00 AM
Grand Ballroom
Peripheral Nerve Society (PNS) Breakfast Symposium (Non-CME)
Moderator:
Luciana León Cejas (Argentina)
8:00 AM - 8:20 AM
Genetic Modifiers in ATTRv
Speaker:
Andrea Cortese (United Kingdom)
8:20 AM - 8:40 AM
Neurological Manifestations in ATTRv
Speaker:
Luciana León Cejas (Argentina)
8:40 AM - 9:00 AM
Update in the Treatment of ATTRv PN
Speaker:
Isabel Conceição (Portugal)
9:00 AM - 10:00 AM
Grand Ballroom
Supportive Care in Amyloidosis. Review of the New ISA Recommendations
Moderators:
Angela Dispenzieri (USA) & Yohei Misumi (Japan)
9:00 AM - 9:10 AM
Supportive Care for Systemic Amyloidosis: International Society of Amyloidosis (ISA) Expert Panel Guidelines
Speaker:
Fabian aus dem Siepen (Germany)
9:10 AM - 9:20 AM
Updated AL Guidelines
Speaker:
Ashutosh Wechalekar (United Kingdom)
9:20 AM - 10:00 AM
Case Discussions
Moderators:
Maria Adela Aguirre (Argentina) & Moshe Gatt (Israel)
10:00 AM - 10:30 AM
Exhibition Room + Florida Room
Coffee Break and Poster Viewing
10:00 AM - 10:30 AM
Florida Room - Poster Station 1
E-poster Session 13 - Treatments of ATTR
Moderator:
Morie Gertz (USA)
10:00 AM - 10:04 AM
The Effectiveness of Tafamidis to Stabilize the Disease Progression of Transthyretin Amyloidosis in Hereditary and Wild-Type Subtypes (#155)
Speaker:
Mounira Kharoubi (France)
10:04 AM - 10:08 AM
Long-Term Durability, Outcomes, and Safety of Nexiguran Ziclumeran Gene Editing in Hereditary Transthyretin Amyloidosis With Polyneuropathy (#156)
Speaker:
Julian D. Gillmore (United Kingdom)
10:08 AM - 10:12 AM
Moderately Accelerated Pacing in Cardiac Amyloidosis (#157)
Speaker:
Timothy Scully (Australia)
10:12 AM - 10:16 AM
Longitudinal Predictors of Therapeutic Escalation in Hereditary Transthyretin Amyloidosis with Polyneuropathy (#158)
Speaker:
Isabel Conceição (Portugal)
10:16 AM - 10:20 AM
Real-World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform (#159)
Speaker:
Shana Littleton (USA)
10:20 AM - 10:24 AM
Real-World Outcomes of SGLT2 Inhibitors Added to Tafamidis in ATTR-CM (#160)
Speaker:
Alexandros Briasoulis (Greece)
10:24 AM - 10:28 AM
Safety of Diflunisal at 250 mg BID for TTR Stabilisation: A Systematic Review Disentangling NSAID Class-Effect Dose-Response From the TTR Stabiliser Pharmacological Profile (#161)
Speaker:
Julian Gillmore (United Kingdom)
10:00 AM - 10:30 AM
Florida Room - Poster Station 2
E-poster Session 14 - Imaging: Cardiac
Moderator:
Claudio Tinoco Mesquita (Brazil)
10:00 AM - 10:04 AM
An Atomistic Model of Bone-Tracer-Based ATTR-CM Diagnosis (#162)
Speaker:
Zoltán Pozsonyi (Hungary)
10:04 AM - 10:08 AM
99mTc-p5+14 (AT-05) is a Pan-Amyloid Imaging Agent That Effectively Detects Cardiac Amyloid by Both Planar and SPECT/CT Imaging at 1 H Post-injection With a High Signal-To-Background Ratio (#163)
Speaker:
Jonathan Wall (USA)
10:08 AM - 10:12 AM
Quantification of Right Ventricular Amyloid Burden With 18F-Florbetaben PET/CT and its Correlation with 99mTc-Pyrophosphate Scintigraphy, Echocardiography and Cardiac Magnetic Resonance in Transthyretin Cardiac Amyloidosis: A Pilot Study (#164)
Speaker:
Adriana Glavam (Brazil)
10:12 AM - 10:16 AM
Significant Correlation Between Structural or Functional Parameters and Cardiac Uptake of the SPECT Radiotracer, 99mTc-p5+14 (AT-05), in Patients With Amyloidosis (#165)
Speaker:
R. Eric Heidel (USA)
10:16 AM - 10:20 AM
Correlation of Quantitative 99mTc-PYP/HDP SPECT/CT Measures to Extracellular Remodeling on Cardiac Magnetic Resonance (#166)
Speaker:
Katrina Case (USA)
10:20 AM - 10:24 AM
Assessing Cardiac Uptake of 124I-Evuzamitide in Patients With Lumbar Spinal Stenosis or Carpal Tunnel Syndrome (#167)
Speaker:
Emily Martin (USA)
10:24 AM - 10:28 AM
Role of Computed Tomography Imaging in Patients With Suspected Cardiac Amyloidosis: Preliminary Results From the MYOAMY Study (#168)
Speaker:
Vincenzo Castiglione (Italy)
10:30 AM - 12:00 PM
Grand Ballroom
Other Subtypes of Amyloidosis (including localized) and Prognostic Models and Treatment Strategies Abstracts
Moderators:
Ute Hegenbart (Germany) & Nelson Leung (USA)
10:30 AM - 10:40 AM
AA Amyloidosis: Looking for the Cause
Speaker:
Marco Basset (Italy)
10:40 AM - 10:50 AM
Genetic Studies for Non-TTR Amyloidosis
Speaker:
Mario Nuvolone (Italy)
10:50 AM - 11:00 AM
ABeta2m
Speaker:
Junichi Hoshino (Japan)
11:00 AM - 11:10 AM
Q&A
11:10 AM - 11:20 AM
MR-proADM Progression is a Prognostic Marker in ATTR-CM (#034)
Speaker:
Mariana Brandão (Spain)
11:20 AM - 11:30 AM
Circulating Plasma Cells for the Prognostic Assessment of AL Amyloidosis (#035)
Speaker:
Arwa Bohra (USA)
11:30 AM - 11:40 AM
Two Variants, Two Origins: Founder Effect and Shared Haplotypes in Brazilian Hereditary Transthyretin Amyloidosis (#036)
Speaker:
Gustavo Alves (United Kingdom)
11:40 AM - 11:50 AM
Expanded Experience of a Multidisciplinary Cardiac Amyloidosis Team: Impact After Five Years of Clinical Practice (#037)
Speaker:
Juan Lorenzo Fraile (Spain)
11:50 AM - 12:00 PM
Dynamic Landmark Prognostic Models Integrating Baseline Characteristics With Evolving Hematologic and Organ Responses to Predict Survival in Light-Chain Amyloidosis (#038)
Speaker:
Xinyi Xiong (China)
12:00 PM - 1:00 PM
Grand Ballroom
ISA Member Meeting
1:00 PM - 2:30 PM
Grand Ballroom
Lunch with Experts - Future Perspectives in Amyloidosis
Moderator:
Stefan Schönland (Germany)
Speakers:
Kevin Alexander (USA), John Clarke (USA), Luis Del Pozo-Yauner (USA), Victor Jimenez-Zepeda (USA) & Peter van der Meer (Netherlands)
2:30 PM - 3:35 PM
Grand Ballroom
Best Abstracts and Closing Ceremony
Moderators:
Shaji Kumar (USA), Eloisa Riva (Uruguay) & Yoshiki Sekijima (Japan)
2:30 PM - 2:40 PM
Longitudinal Multimodal Imaging and Proteomics Reveal Mechanistic Drivers of Disease Progression in a Preclinical Model of Transthyretin Amyloid Cardiomyopathy (#039)
Speaker:
Philippa Garbutt (United Kingdom)
2:40 PM - 2:50 PM
A Small Absolute dFLC Increase Predicts Organ Progression With a Median Lead Time of Five Months in AL Amyloidosis (#040)
Speaker:
Despina Trajanova (Germany)
2:50 PM - 3:00 PM
Transthyretin Amyloid Cardiomyopathy Staging in the Disease-Modifying Therapy Era: Validation and Temporal Trends (#041)
Speaker:
Bilal Ansari (USA)
3:00 PM - 3:10 PM
CryoEM of Human Light Chain Amyloids Reveals How Amino Acid Composition and Microenvironment Shape Pathologic Amyloid Conformations (#042)
Speaker:
Noorul Huda (USA)
3:10 PM - 3:20 PM
Representativeness and Clinical Trial Eligibility in a Contemporary Real-World ATTR-CM Cohort (#043)
Speaker:
Mariana Brandão (Spain)
3:20 PM - 3:30 PM
Outpatient Worsening Heart Failure Independently Predicts Composite of Death and First Heart Failure Hospitalization Alongside Functional and Biomarker Assessments in ATTR-CM (#044)
Speaker:
Bilal Ansari (USA)
3:35 PM - 4:50 PM
Conference Room
Special Session ISA/LATAM: Opportunities for Collaboration
Moderators:
Eloisa Riva (Uruguay) & Yoshiki Sekijima (Japan)
3:35 PM - 3:40 PM
Introduction
Speaker:
Yoshiki Sekijima (Japan)
3:40 PM - 3:50 PM
Patient Perspective
Speaker:
Barbara Coelho (Brazil)
3:50 PM - 4:10 PM
Challenges in the Current Diagnosis and Management of Amyloidosis in LATAM - Expanding Access to Diagnosis and Treatment - Building Effective Programs and Developing Multidisciplinary Care Teams
Speakers:
Maria Adela Aguirre (Argentina), Erika Brulc (Argentina) & Phillip Scheinberg (Brazil)
4:10 PM - 4:20 PM
Amyloidosis Registries: Opportunities to Contribute to Global Knowledge
Speaker:
Alejandra Gonzalez-Duarte (Mexico)
4:20 PM - 4:35 PM
LATAM Research Projects
Speakers:
Eloisa Riva (Uruguay) & Marcia Waddington (Brazil)
4:35 PM - 4:50 PM
Panel Discussion: Establishing and Growing Regional Working Groups - Key priorities for LATAM-ISA
Speakers:
Erika Brulc (Argentina), Alejandra Gonzalez-Duarte (Mexico), Eloisa Riva (Uruguay), Phillip Scheinberg (Brazil), Yoshiki Sekijima (Japan) & Marcia Waddington (Brazil)
Unmoderated Posters - Monday
Unmoderated Posters - Monday
Interim Results of a Phase I/II, Open Label, Study to Evaluate Safety, Tolerability, and Efficacy of Elranatamab in Patients With Relapsed AL Amyloidosis (#169)
Speaker:
Giada Bianchi (USA)
Phenotypic Expansion of the Ultra-Rare TTR Gly87Arg Variant: First Brazilian Case of Hereditary Transthyretin Amyloidosis (#170)
Speaker:
Marcelo Cruzeiro (Brazil)
Cure Fraction in Systemic AL Amyloidosis: Population-Adjusted Estimates and Characteristics of Long-Term Survivors (#171)
Speaker:
Vaishali Sanchorawala (USA)
Dimer Dissociation and Aggregation Hot-spot Exposure Synergistically Accelerate Light Chain Variable Domain Aggregation Associated With AL Amyloidosis (#172)
Speaker:
Sarita Puri (India)
Impact of Socioeconomic Factors on Outcomes in AL Amyloidosis (#173)
Speaker:
Maximilian Steinhardt (USA)
LATAM Amyloidosis Registry: Sex- and Subtype-Specific Outcomes in a Multicenter Cohort (#174)
Speaker:
Marcelina Carretero (Argentina)
The Critical Role of the Variable Domain in Driving Proteotoxicity and Aggregation in Full-length Light Chains (#175)
Speaker:
Sarita Puri (India)
The Value of Bone Scintigraphy Following Orthopaedic Red Flags for ATTR Amyloidosis (#177)
Speaker:
Arne Decramer (Belgium)
Echocardiography-Based Artificial Intelligence for Cardiac Amyloidosis Detection: Diagnostic Performance, Heterogeneity, and Validation Gaps (#178)
Speaker:
Claudio Tinoco Mesquita (Brazil)
A Light Chain Amyloidosis Model in Kidney Organoids Demonstrates That Attenuation of CDK1-Mediated EMT Resolves Podocytopathy and Tubulointerstitial Fibrosis (#179)
Speaker:
Navin Gupta (USA)
Teclistamab in Relapsed/Refractory AL Amyloidosis: A Retrospective Study by a National Society for Amyloid Diseases (#180)
Speaker:
Alexander Carpinteiro (Germany)
Extensive Right Ventricular Uptake on 99mTc-Pyrophosphate Scintigraphy as a Marker of Poor Prognosis in Transthyretin Amyloid Cardiomyopathy: Experience of a Tertiary University Hospital (#181)
Speaker:
Adriana Glavam (Brazil)
Cardiac Insights and Early Findings From MaesTTRo: Exploring Transthyretin Amyloidosis Through a Prospective Multi-National Real-World Study (#182)
Speaker:
Margot. K Davis (Canada)
Clinical Phenotype and Outcomes of Early- Versus Late-Onset ATTRwt Cardiomyopathy (#183)
Speaker:
Giacomo Tini (Italy)
Comprehensive Screening & Monitoring for Systemic Immunoglobulin Light Chain (AL) Amyloidosis in Patients with Monoclonal Gammopathy of Clinical Significance (COSMO-AL) (#184)
Speaker:
Max Rieger (Switzerland)
Improving Diagnostic Timelines in AL Amyloidosis: Trends From the ARC Community Survey, 2022–2025 (#185)
Speaker:
Kristen Hsu (USA)
Prevalence of Lumbar Ligamentum Flavum Amyloidosis and Cardiac Amyloidosis in a General Autopsy Cohort: Afflictions of the Elderly (#186)
Speaker:
Ellen McPhail (USA)
Amyloidogenic Light Chain-Induced Cytotoxicity and Calcium Dysregulation in Human Cardiac Models of AL Amyloidosis (#187)
Speaker:
Monique Minnema (Netherlands)
Molecular Basis for the Pro-amyloidogenic Action of a Novel W72R Variant of Human Apolipoprotein A-I (#188)
Speaker:
Noorul Huda (USA)
Falls and Fractures Drive Increased Hospitalizations and Costs in Patients With Transthyretin Amyloid Cardiomyopathy Compared With Controls (#189)
Speaker:
Liana Hennum (USA)
Left Atrial Emptying Fraction by Simple Standard 2D Echocardiography Predicts Mortality in AL Amyloidosis (#190)
Speaker:
Valeria Anna Di Simone (Italy)
Improvements in Cardiac Functional Status and Health-Related Quality of Life in Patients Receiving Early Access Tafamidis (#191)
Speaker:
Margot. K Davis (Canada)
Transthyretin Stabilization is Associated With Sustained Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy: Insights From ATTR-ACT (#192)
Speaker:
Valentina Marino (Italy)
Assessing ATTR-CM Progression in France: A Case-Vignette Study (#193)
Speaker:
Thibaud Damy (France)
Transthyretin as a Static and Dynamic Biomarker of Disease Trajectory in Transthyretin Cardiac Amyloidosis: Insights from the French HEAR Registry (#194)
Speaker:
Mounira Kharoubi (France)
Age-Dependent Sex Differences and Treatment-Associated Outcomes in Transthyretin Wild-Type Cardiac Amyloidosis: A Nationwide Multicenter Study (#195)
Speaker:
zaroui amira (France)
Associations of microRNAs Gene Expression and Left Ventricular Global Longitudinal Peak Strain in Patients With TTR Amyloidosis (#196)
Speaker:
spyridon maragkoudakis (Greece)
Long-Term Kidney Allograft Outcomes After Transplantation in AL Amyloidosis (#197)
Speaker:
Si Yuan Khor (USA)
The Importance of Distinct Cardiac MRI Regional Analyses to Assess the Effects of Cliramitug on Amyloid Depletion From the Phase 1 Study NI006-101 (#198)
Speaker:
Fabian aus dem Siepen (Germany)
Clinicopathologic and Proteomic Analysis of Keratin-type Amyloidosis (#199)
Speaker:
Ellen McPhail (USA)
Amyloid-Dependent Modulation of Macrophage Polarization and Cytokine Responses in AL Amyloidosis (#200)
Speaker:
Manasi Balachandran (USA)
Are Patients With ATTRv Amyloidosis Being Left Behind in Clinical Research? Patient-Reported Trends in Trial Enrollment, 2022–2025 (#201)
Speaker:
Kristen Hsu (USA)
NT-proBNP and Serum Transthyretin and Their Relationship With Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM (#202)
Speaker:
Onyedika J. Ilonze (USA)
Effect of Acoramidis on the Temporal Variability of Serum Transthyretin and its Influence on Outcomes: Insights From the ATTRibute-CM Trial (#203)
Speaker:
Prem Soman (USA)
Long-term Improvement in Myocardial Structure and Function in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treated With Acoramidis Compared With a Natural History Cohort (#204)
Speaker:
Awais Sheikh (United Kingdom)
Carpal Tunnel Biopsy Screening for Transthyretin Amyloidosis Across Independent European Cohorts (#205)
Speaker:
Sie Kronborg Fensman (Denmark)
Clinical Profile of F64L ATTRv Patients: Evidence From a Multicenter Italian Study (#206)
Speaker:
Marco Ceccanti (Italy)
Cardiac Amyloidosis in Heart Failure With Preserved Ejection Fraction: Frequency and Diagnostic Approach in a Tunisian Cohort (#207)
Speaker:
Saoussen Antit (Tunisia)
Conventional Heart Failure Medication in Immunoglobulin Light-Chain Cardiac Amyloidosis (#208)
Speaker:
Paolo Milani (Italy)
Real-World Characteristics and Treatment Patterns Among New Vutrisiran Patients With ATTR-CM (#209)
Speaker:
Sumeet Mitter (USA)
CARM-8: A Next-Generation PGR-Based Chimeric Antigen Receptor Macrophage With Enhanced Amyloid Recognition and Clearance (#210)
Speaker:
Manasi Balachandran (USA)
Hidden Hepatic Involvement in Systemic AL Amyloidosis: The Role of Two-Dimensional Shear Wave Elastography (#211)
Speaker:
Olga Pirogova (Russia)
Multifocal Surrogate Biopsy Strategies in Systemic AL Amyloidosis. Single-Center Study (#212)
Speaker:
Olga Kudyasheva (Russia)
Teclistamab Plus Daratumumab in Newly Diagnosed AL Amyloidosis: Interim Results From the Phase 2 IMPACT-AL Trial (#213)
Speaker:
Rajshekhar Chakraborty (USA)
Light-Chain Amyloidomas of the CNS: Imaging Characterization and Long-term Follow Up (#214)
Speaker:
Jennifer Hayes (USA)
Sex-Based Clinical, Imaging, and Prognostic Differences in Transthyretin Amyloid Cardiomyopathy in a Latin American Referral Center (#215)
Speaker:
Florencia Cantora (Argentina)
Rare Coexistence of Dual Pathogenic Variants in the TTR Gene: A Case Series (#216)
Speaker:
Larissa Bruscky (Brazil)
Large-Fiber Peripheral Neuropathy in Wild-Type Transthyretin Amyloidosis: An Underrecognized Cause of Functional Impairment (#217)
Speaker:
Ava Bakhtyari (USA)
Extended Validation of SMaRT M-Seq for Clonal Light Chain Sequencing in Monoclonal Gammopathies (#218)
Speaker:
Alice Nevone (Italy)
Cardiac Outcomes and Survival by Light Chain Isotype in Advanced Light Chain (AL) Amyloidosis: A French Multicenter Analysis From the HEAR Registry (#219)
Speaker:
Mounira Kharoubi (France)
Comparative Prognostic Value of Short Physical Performance Battery Versus 6-Minute Walk Distance in Transthyretin Amyloid Cardiomyopathy (#220)
Speaker:
Sarah Cuddy (USA)
Structural Characterization of Kappa Amyloid Fibrils Derived From Cardiac AL Amyloidosis Patient (#221)
Speaker:
Stefano Ricagno (Italy)
Amyloid Opsonization Circumvents Amyloid-Induced Cellular Toxicity in Macrophages (#222)
Speaker:
Joseph Jackson (USA)
Increased Serum Transthyretin Concentration After Starting Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy Is Associated With Lower Risk of Recurrent Outpatient Worsening Heart Failure (#223)
Speaker:
Bilal Ansari (USA)
Skin Biopsy Biomarkers in ATTRv Amyloidosis: An Evidence Maturity Framework for Diagnosis, Monitoring, and Translational Readiness (#224)
Speaker:
Kwaku Appiah-Kubi (Ghana)
Stabilizer Treatment in Nonagenarian Patients With Transthyretin Cardiac Amyloidosis: Candidates for Treatment? Data From the National Attracking Registry (#225)
Speaker:
Rafael Martín-Portugés (Spain)
High-Sensitivity Cardiac Troponin I Progression Criteria in Transthyretin Cardiac Amyloidosis (#226)
Speaker:
Clea González-Maniega (Spain)
Sex-Associated Differences Post-diagnosis of Wild-Type Transthyretin Amyloidosis Cardiomyopathy - An Overtture Analysis (#227)
Speaker:
Kevin Alexander (USA)
Polybasic PxR Peptides Are Novel, Potent Pan-Amyloid-Binding Peptides (#228)
Speaker:
Trevor Hancock (USA)
Mapping the Gaps: A Geospatial Exploration of Light Chain (AL) Amyloidosis Cases Relative to Amyloid Centers in the United States (#229)
Speaker:
Anita DSouza (USA)
Single-Center Experience of Amyloid Typing: A Shifting Cardiac-to-Musculoskeletal Tissue Source for ATTR and Underrecognized Coexisting Amyloidosis (#230)
Speaker:
Mitsuharu Ueda (Japan)
Left Atrial Reservoir Strain and Clinical Disease Progression in Tafamidis-Treated Wild-Type Transthyretin Amyloid Cardiomyopathy: Insights From the iNERVE Study (#231)
Speaker:
Denise Cristiana Faro (Netherlands)
Preliminary Efficacy and Safety of TQB2934, a BCMA×CD3 Bispecific Antibody, in Chinese Patients With Relapsed/Refractory AL Amyloidosis (#232)
Speaker:
Yang Liu (China)
Screening for Cardiac Amyloidosis in Patients With Newly Identified Conduction Disease (#233)
Speaker:
Timothy Scully (Australia)
Is Prolonged Daratumumab Maintenance Useful in Light-Chain Amyloidosis? (#234)
Speaker:
Kaini Shen (China)
Secondary Transcriptomic Reanalysis of Extracellular TTR Fibril Exposure Identifies Convergent Endothelial Responses in a Human in Vitro Model of ATTR-CM (#235)
Speaker:
Inés Losada (Spain)
Diagnostic Value of Myocardial Work in the Etiological Differentiation of Left Ventricular Hypertrophy (#236)
Speaker:
Saoussen Antit (Tunisia)
Central Hemodynamics and Arterial Stiffness in Transthyretin Cardiac Amyloidosis: Insights From Non-invasive Pulse Wave Analysis (#237)
Speaker:
Gina Barzen (Germany)
Real-World Functional and Neurological Outcomes in Patients With Wild-Type Transthyretin Amyloidosis Treated With Vutrisiran (#238)
Speaker:
José Ángel Urbano-Moral (Spain)
Effects of a Virtual Exercise Training Program on Physical Performance and Quality of Life in Patients With Cardiac Amyloidosis (#239)
Speaker:
Katharina Knoll (Germany)
Heart Failure Treatment Patterns in Patients With Transthyretin Amyloid Cardiomyopathy and Diagnosed Heart Failure in the United States (#240)
Speaker:
Sumeet S Mitter (USA)
Development and Implementation of a Supportive Care Pathway for Patients With AL Amyloidosis (#241)
Speaker:
Anne Møller Clausen (Denmark)
Treatment Effect of Vutrisiran on Measures of Polyneuropathy in HELIOS-B (#242)
Speaker:
Yoshiki Sekijima (Japan)
Disease Stabilization in Patients With Transthyretin Amyloid Cardiomyopathy During the First Year of Tafamidis Treatment (#243)
Speaker:
Pablo Garcia-Pavia (Spain)
Amyloidosis Project ECHO (Extension for Community Healthcare Outcomes): Strengthening healthcare provider knowledge on TTR (Transthyretin Amyloidosis) and Light Chain Amyloidosis (AL)care Light Chain Amyloidosis (Al)Care Through Expert-Informed, Peer-To-P (#244)
Speaker:
Alyssa Galloway (USA)
Preoperative Amyloid Red Flags Identify Patients With Congo Red-Positive Aortic Valve Deposits Among Those Undergoing Surgical Aortic Valve Replacement for Severe Aortic Stenosis (#245)
Speaker:
Giuseppe Vergaro (Italy)
Recovery of NT-proBNP Concentrations and Heart Failure-Related Health Status After Cardiovascular-Related Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM (#246)
Speaker:
Prem Soman (USA)
Disease Progression and Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis (#247)
Speaker:
Pablo Garcia-Pavia (Spain)
CryoEM of Spleen-Derived IGLV1-51 Al Amyloid Reveals Polymorphic Fibrils With Non-native Disulfide Pairing (#248)
Speaker:
Noorul Huda (USA)
Safety and Efficacy of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and CKD Stage 4: Insights From the ATTRibute-CM Trial (#249)
Speaker:
Prem Soman (USA)
Effect of Background RAAS Inhibitor Use on Cardiorenal Function and Clinical Outcomes With Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM (#250)
Speaker:
Prem Soman (USA)
Chromosome 1q21 Aberrations as Prognostic Biomarkers in Asia-Pacific AL Amyloidosis Patients Treated With Daratumumab-Based First-Line Regimens (#251)
Speaker:
Guixiang Duan (China)
Estimation of Age and Sex Adapted Incidence of ATTRwt Amyloidosis in an European Country From a Prospective National Clinical Amyloidosis Registry (#252)
Speaker:
Ute Hegenbart (Germany)
Diagnostic Comparison of Congo Red-Stained Fat Pad Aspirates Processed as Smears vs. Formalin-Fixed Paraffin-Embedded Sections (#253)
Speaker:
Florencia Rojas-Miguez (USA)
Ocular Manifestations in Hereditary Transthyretin Amyloidosis: A Retrospective Study of Swedish Patients (#254)
Speaker:
Intissar Anan (Sweden)
Reduced Distal-leg Intraepidermal Nerve Fiber Density as an Early Biomarker of Small-Fiber Neurodegeneration Across the Hereditary Transthyretin Amyloidosis Disease Continuum: A Systematic Review and Meta-analysis (#255)
Speaker:
Kwaku Appiah-Kubi (Ghana)
The Analysis for the Transthyretin C-Terminal Fragment in ATTRv Amyloidosis (#256)
Speaker:
Tomoaki Taguchi (Japan)
eGFR Dip After Acoramidis Initiation and Acoramidis-Associated Clinical Benefits in Patients With Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings From the ATTRibute-CM Trial (#257)
Speaker:
Kevin M. Alexander (USA)
Genetic Spectrum and Geographic Distribution of TTR Variants in Latin America (#258)
Speaker:
Mauricio Tomei (Argentina)
Clinicopathologic, Outcome, and Proteomic Characteristics of Renal Heavy Chain Amyloidosis (#259)
Speaker:
Samih Nasr (USA)
Sex-Specific Differences in Early Clinical Presentation and Disease Progression in Wild-Type Transthyretin Amyloidosis (ATTRwt) (#260)
Speaker:
Gina Barzen (Germany)
Disease-Specific Molecular Signatures of Pathogenic Monoclonal Light Chains Enable Improved Identification of Amyloidogenic Light Chains (#261)
Speaker:
Christophe Sirac (France)
Variable Intrafamilial Phenotypic Expression Associated With the I84N (p.Ile104Asn) Variant in Hereditary Transthyretin Amyloidosis (#262)
Speaker:
Lucas Pereira (USA)
Frequency of Genetic Variants in TTR, Plasma Transthyretin Concentration, Stability Scores, and Risk of Amyloidosis-Related Cardiac Disease in the General Population (#263)
Speaker:
Anne Tybjærg Hansen (Denmark)
Performance of 99mTc-p5+14 (AT-05) for the Detection of Cardiac Amyloid in Patients With Biopsy-Proven ATTR Amyloidosis and Equivocal 99mTc-PYP Imaging at Diagnosis (#264)
Speaker:
Alan Stuckey (USA)
Histological Findings of Pharmacology Associated With Zamubafusp Alfa (AT-02) Infusions in a Patient With Cardiac ATTR Amyloidosis (#265)
Speaker:
Jonathan Wall (USA)
AmyLife: An International Patient-Reported Survey Characterizing Disease Burden, Diagnostic Journey, and Quality of Life in Amyloidosis (#266)
Speaker:
Julian Gillmore (United Kingdom)
Real-World Evidence (RWE) on ATTR-CM in Switzerland: A Registry-Based Analysis (#267)
Speaker:
Julian Conrad (Switzerland)
Quick Identification of ATTR-CM Whole-waveform ECG Change Associated With Deterioration via a Visual Clinical Decision Support Tool – The Symmetric Projection Attractor Reconstruction (SPAR) (#268)
Speaker:
Miquel Serna Pascual (United Kingdom)
Spread-ATTR: Major Educational Gains in Medical Students Despite the Challenge of Institutional Resistance in Primary Care (#269)
Speaker:
BRUNO BUENO (Brazil)
Aerobic Capacity Improvement After Hematologic Response in Light-Chain Cardiac Amyloidosis (#270)
Speaker:
Arielle Abovich (USA)
Soft-Tissue DPD Uptake as a Biomarker of ATTR Polyneuropathy and Its Correlation With Pathogenic Variants: A Single-Center Retrospective Study (#271)
Speaker:
Rodrigo Hernandez Ramirez (Mexico)
Characterizing the Cardiotoxic and Non-cardiotoxic Effects of Amyloidogenic Light Chains on Second-Messenger Signaling in Human Cardiac Fibroblasts (#272)
Speaker:
Doruk Kaan Bayburtlu (Italy)
Presymptomatic Screening With Strict Clinical Follow-Up Enhances Early Treatment of Transthyretin Amyloidosis With Polyneuropathy (#273)
Speaker:
Gustavo Maximiano-Alves (Brazil)
Cardiac Echocardiography, Global Longitudinal Strain and Baseline Biomarkers in a Single-Centre Al Amyloidosis Cohort Under Contemporary Therapy (#274)
Speaker:
David Scheer (Germany)
Bispecific Antibodies in Relapsed/Refractory AL Amyloidosis: Long-Term Efficacy, Infectious Complications, and Survival Outcomes from a Multi-Center Cohort (#275)
Speaker:
Rajshekhar Chakraborty (USA)
Day 25 MRD Negativity Predicts Subsequent Hematologic Complete Response and Organ Response Following NXC-201 CAR-T in Relapsed/Refractory AL Amyloidosis (#276)
Speaker:
Heather Jolie Landau (USA)
Prevention of ATTR Amyloidosis by Nucresiran Treatment in a Transgenic Mouse Model (#277)
Speaker:
Josephine Humphries (United Kingdom)
Electrochemical Skin Conductance Demonstrates Progressive Sudomotor Dysfunction Across ATTRv Amyloidosis Disease Continuum: A Systematic Review and Meta-analysis (#278)
Speaker:
Kwaku Appiah-Kubi (Ghana)
Treatment of Relapsed/Refractory Systemic Light Chain Amyloidosis With the Novel CD28-harboring MDC-CAR-BCMA001 CAR T-Cell: Experience So Far and Prospective Trial (#279)
Speaker:
Stefan Schönland (Germany)
Contemporary, Real World Outcomes of ATTR Cardiac Amyloidosis (#280)
Speaker:
Jacob Beery (USA)
Baseline Cardiac Sympathetic Function Assessed by [¹²³I]-MIBG Scintigraphy Is Associated With Disease Severity and Progression in Transthyretin Cardiac Amyloidosis: The I-Nerve Study (#281)
Speaker:
Ilse Jonkhof (Netherlands)
Enhanced Phagocytic Clearance of Kappa AL Amyloid by a Humanized, Conformation-Specific Antibody (#282)
Speaker:
Yulong Sun (Canada)
Exploring the Benefits of a Mainstream Genetic Counsellor Within a National Amyloidosis Centre; Insights From Clinical Case Studies (#283)
Speaker:
Emily Dixon (United Kingdom)
Remodeling of the Bone Marrow Myeloid Compartment Is Associated With an Immunosuppressive Microenvironment in AL Amyloidosis (#284)
Speaker:
Jackson Smith (USA)
Survival in a Contemporary, Real-World, Matched Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated With Tafamidis (#285)
Speaker:
Fabian aus dem Siepen (Germany)
Low-Frequency TTR Variants Identified Through a Regional Diagnostic Program in Latin America (#286)
Speaker:
Mauricio Tomei (Argentina)
Automated Quantification of Serial 123I-Serum Amyloid P Component (SAP) Scintigraphy Reveals Organ-Specific Amyloid Regression Kinetics in AL Amyloidosis (#287)
Speaker:
Yingqi Hu (Netherlands)
Clinical Impact of Subcutaneous Fat Aspirate in Avoiding Endomyocardial Biopsy in Systemic Amyloidosis With Cardiac Involvement (#288)
Speaker:
Patrick L S Michel (Italy)
Real-World Effectiveness of Vutrisiran in Hereditary Transthyretin Amyloidosis: Sustained Clinical Stability Over 18 Months (#289)
Speaker:
Carla Fasano (Italy)
18F-Florbetaben-PET/CT Extracardiac Uptake in Patients With Suspected Cardiac Amyloidosis: Prevalence, Distribution, and Prognostic Significance (#290)
Speaker:
Vincenzo Castiglione (Italy)
Screening for AL Amyloidosis in Smoldering Multiple Myeloma: Update on a Nationwide Study (#291)
Speaker:
Colin Kloock (USA)
L-Arginine-Mediated Disaggregation of Amyloid-like Crystallin Aggregates in Human Cataractous Lens (#292)
Speaker:
Tanishka Sharma (India)
REACT: A Pre-specified Point Score to Rule in Transthyretin Amyloidosis Without Biopsy in the Monoclonal-Gammopathy Gray Zone (#293)
Speaker:
Marc-Antoine Delbarre (France)
Conventional Chronic Kidney Disease Medication in AL Amyloidosis With Kidney Involvement (#294)
Speaker:
Marco Basset (Italy)
When Should a Patient With Hereditary Transthyretin Amyloidosis Be Considered to Have Clinically Relevant ATTR-CM? Experience From a Brazilian Referral Center (#295)
Speaker:
Fabio Souza (Brazil)
Prevalence, Correlates, and Prognostic Value of Anemia in Cardiac Amyloidosis (#296)
Speaker:
Vincenzo Castiglione (Italy)
Real-World Outcomes of Tafamidis Monotherapy Versus Combination Therapy in Transthyretin-Related Amyloidosis (#297)
Speaker:
Alexandros Briasoulis (Greece)
Prognostic Value of CMR-Derived Right Ventricular Global Longitudinal Strain in Light-Chain (AL) Cardiac Amyloidosis (#298)
Speaker:
Alexandros Briasoulis (Greece)
First-line Daratumumab–Lenalidomide–Dexamethasone in Newly Diagnosed Systemic AL Amyloidosis: A UK National Amyloidosis Centre Experience (#299)
Speaker:
Suraj Vasudevan (United Kingdom)
Severity of Interstitial Fibrosis and Tubular Atrophy on Kidney Biopsy and Renal Outcomes in AL Amyloidosis (#300)
Speaker:
Alec Seidman Sorsby (USA)
Venetoclax, Ixazomib, and Dexamethasone for Relapsed/Refractory AL Amyloidosis: Results of the Phase 1/1A Multicenter VIDA Study (#301)
Speaker:
Michael Rosenzweig (USA)
Aerobic Capacity and Cardiac Status After Hematologic Response in Light-Chain Cardiac Amyloidosis (#302)
Speaker:
Or-El Ankori (USA)
Diagnostic Utility of Circulating Clonal Plasma Cells in Systemic Light-Chain (AL) Amyloidosis (#303)
Speaker:
Douglas Peters (USA)
Cardiovascular Reflex Tests as Early Potential Markers of Disease-Modifying Treatment Eligibility in Asymptomatic ATTRv Carriers: Proposal of the “Two or More Rule” (#304)
Speaker:
Micol Gianoli (Italy)
Sequence and Spatial Features of N-glycosylation Correlate With Clonal Kappa Light Chain Pathogenicity (#305)
Speaker:
Alice Nevone (Italy)
Monoclonal Gammopathy of Undetermined Significance in Hereditary ATTRV30M Amyloidosis: Dissimilarities From Wild-Type (#306)
Speaker:
Ana Cunha (Portugal)
Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis (#307)
Speaker:
Ligia Facin (Brazil)
Direct Detection of Transthyretin Misfolding in Plasma Before Amyloid Deposition Enables Early Diagnosis of Transthyretin Amyloidosis (#308)
Speaker:
Sandra Pankow (USA)
Large-Scale Uniform M-Protein Sequencing Establish Genotype–Phenotype Correlations in AL Amyloidosis and Multiple Myeloma (#309)
Speaker:
Alice Nevone (Italy)
Contemporary, Real-World Outcomes in AL Amyloidosis: Interim Results From the International Prospective Eureka Study (#310)
Speaker:
Mario Nuvolone (Italy)
Estimation of Age and Sex Adapted Incidence of AL Amyloidosis in an European Country From a Prospective National Clinical Amyloidosis Registry (#311)
Speaker:
Stefan Schönland (Germany)
Impact of BMPC in the Outcome of Patients with Light Chain (AL) Amyloidosis Treated With Daratumumab-based Therapies (#312)
Speaker:
Foteini Theodorakakou (Greece)
Role of Vitronectin in TTR Amyloidogenesis (#313)
Speaker:
Guglielmo Verona (United Kingdom)
Impaired Right Ventricular Free Wall Strain Predicts All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy Receiving Disease-Modifying Therapy (#314)
Speaker:
Stéphanie Kristina Schwarting (Germany)
Changes Over Time in Holter Monitoring Findings and the Clinical Significance of Non-sustained Ventricular Tachycardia in a Cohort of Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis (#315)
Speaker:
Valentina Carini (Italy)
Splenic Uptake on ¹²⁴I-evuzamitide PET/CT Distinguishes AL From ATTR Amyloidosis (#316)
Speaker:
Sharmila Dorbala (USA)
Penetrance of Extracardiac Manifestations in Carriers of The TTR V122I (p.Val142Ile) Variant (#317)
Speaker:
Lucas Pereira (USA)
Triple-Negative M-Protein Studies in Al Amyloidosis: Detecting Clinically Relevant Small Plasma Cell Clones (#318)
Speaker:
Alice Nevone (Italy)
Beyond TTR V122I: From Single-Variant Epidemiology to a Multi-Variant Precision Screening Framework for Pre-Transplant TTR Genetic Testing in West Africa (#319)
Speaker:
Kwaku Appiah-Kubi (Ghana)
Diagnostic Delay in Hereditary Transthyretin Amyloidosis: Are We Making Progress? (#320)
Speaker:
Roberta Mussinelli (Italy)
Carpal Tunnel Syndrome (CTS) in ATTRv Val122Ile: A Window for Early Diagnosis (#321)
Speaker:
Carolina Lavigne Moreira (Brazil)
Comparative Characteristics of Patients With and Without Transthyretin Amyloid Cardiomyopathy in the TTRACK Study Population (#322)
Speaker:
Thibaud Damy (France)
Rapid Diagnosis Using Fluorescently Labeled Monoclonal Anti-amyloid Antibodies (#323)
Speaker:
Gunilla Westermark (Sweden)
An Interventional Pilot Study on the Feasibility and Acceptance of a Psychological Support Program for Patients, Caregivers, and Asymptomatic Carriers in Hereditary Transthyretin Amyloidosis (#324)
Speaker:
Roberta Mussinelli (Italy)
Safety of Kidney Biopsy in Kidney Amyloidosis: Complications in a Nationwide Cohort (#325)
Speaker:
Hilde Jaeger Vasstrand (Norway)
Sex Differences in Left Ventricular Cardiac Amyloid: An Autopsy Study (#326)
Speaker:
Ethan Hortelano (USA)
Comparison of Quantitative Positron Emission Tomography Metrics in Cardiac Amyloidosis (#327)
Speaker:
Olivier Clerc (USA)
Sensitivity of Electrocardiographic Voltage Indices for Monitoring Disease Progression in ATTR Cardiac Amyloidosis (#328)
Speaker:
Marina Santos (Brazil)
Unmoderated Posters - Tuesday
Unmoderated Posters - Tuesday
Venetoclax in IgM-Associated AL Amyloidosis: A Multicenter Retrospective Analysis (#329)
Speaker:
Maximilian Steinhardt (USA)
Long-Term Hematologic and Organ Outcomes of First-Line DVCd in Systemic AL Amyloidosis (#330)
Speaker:
Maximilian Steinhardt (USA)
Describing the Diagnostic Journeys of Transthyretin Amyloid Cardiomyopathy Patients in the United States: A Real-World Survey (#331)
Speaker:
Ann Willet (USA)
The Role of Palliative Care in the Multidisciplinary Treatment of Light Chain Amyloidosis: A Retrospective Case Series (#332)
Speaker:
Pedro Vianna (USA)
The Conformational Landscape of AlphaFold2-Predicted Amyloidogenic Light Chains and Their Correlation With VL Domain Mutations and Aggregation Propensity (#333)
Speaker:
Sarita Puri (India)
Clinical, Genetic and Phenotypic Characterization of Hereditary Transthyretin Amyloidosis (ATTRv) in Peruvian Population: Real-World Data From a Case Series (#334)
Speaker:
Javier Torres Valencia (Peru)
A Pedigree Analysis Associating a Rare TNFRSF1A p.Thr90Pro Variant With TNF-receptor Associated Periodic Fever Syndrome and AA Amyloidosis (#335)
Speaker:
Lucas Pereira (USA)
Survival and Disease Burden in Systemic Light-Chain Amyloidosis: A Retrospective Cohort Study (#336)
Speaker:
Delfina Cirelli (Argentina)
A Decision-Guided CryoSPARC Workflow for Reconstruction of Heterogeneous Patient-Derived AL Amyloid Fibrils (#337)
Speaker:
Noorul Huda (USA)
Changing Autologous Stem Cell Transplantation (ASCT) Practice in Light Chain (AL) Amyloidosis in the US. (#338)
Speaker:
Remy Lee (USA)
Treatment Impact on Renal Response and Renal Survival in Patients With AL Amyloidosis and Renal Involvement: A Retrospective Cohort Study (#339)
Speaker:
Delfina Cirelli (Argentina)
Oral Diuretic Intensification in Real-World ATTR-CM Patients on TTR Stabilizing Therapy: The mODIficATTR Study (#340)
Speaker:
Roman Pfister (Germany)
Longitudinal Changes in PYP Heart-to-Contralateral Lung Ratio and Echocardiographic Diastolic Parameters in ATTR Cardiac Amyloidosis Treated With Tafamidis (#341)
Speaker:
Dimitar Saveski (Canada)
Quantitative 99mTc-PYP SPECT/CT for ATTR-CA Diagnosis: Comparison of SUVmax, Myocardium-to-Blood and Myocardium-to-Bone Metrics (#342)
Speaker:
LUCIANO SANTOS (Uruguay)
Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy: Early Real-World Evidence Favors Acoramidis (#343)
Speaker:
Daniel P. Judge (USA)
Long-term Cardiac Outcomes in Hereditary Transthyretin Amyloidosis Patients Treated With siRNA Therapies: A Real-World Cohort (#344)
Speaker:
Vincent ALGALARRONDO (France)
Long-Read Sequencing in Al Amyloidosis: Why Sequencing the Constant Domain Matters (#345)
Speaker:
Eyad Naser (Germany)
Long-Term Treatment With Tafamidis in ATTR-CM: 7.5-Year Outcomes From the Phase 3 Open-Label Long-Term Extension Study (#346)
Speaker:
Thibaud Damy (France)
The Effect of Quality of Life on All-Cause Mortality in Tafamidis- vs. Placebo-Treated ATTR-CM Patients: Post-hoc Analyses From the ATTR-ACT Study (#347)
Speaker:
Thibaud Damy (France)
Longitudinal Assessment of ATTR-QOL Questionnaire and KCCQ-OS in Transthyretin Amyloid Cardiomyopathy: A Prospective Cohort Study (#348)
Speaker:
Dimitrios Bampatsias (USA)
Building on the Demonstrated Functional Benefit of Tafamidis: Association of TTR Stabilization With 6MWT Outcomes in ATTR-ACT (#349)
Speaker:
Stefano Perlini (Italy)
Estimated Glomerular Filtration Rate Trajectories by Transthyretin Stabilization Status in ATTR-ACT (#350)
Speaker:
Stefano Perlini (Italy)
Outcomes With Early Access Tafamidis in Patients With Variant Transthyretin Amyloid Cardiomyopathy (#351)
Speaker:
Valentina Marino (Italy)
Pre-treatment Glomerular Transcriptomics Reveals Stage-Dependent Phenotypes in Renal AL Amyloidosis (#352)
Speaker:
Charalampos Charalampous (USA)
Genotype Influences the Relationship Between Tc99m-PYP Cardiac Uptake and Structural Disease Severity in Transthyretin Cardiac Amyloidosis (#353)
Speaker:
Marcus Simoes (Brazil)
Isatuximab, Pomalidomide and Dexamethasone in Relapsed Al Amyloidosis: Final Results of the ISAMYP Phase 2 Study (#354)
Speaker:
Murielle Roussel (France)
Single-Center Real-World Experience With MRD in AL Amyloidosis (#355)
Speaker:
Charlotte Toftmann Hansen (Denmark)
Val142Ile Is Not Exclusively a Cardiac Variant: Neurological Presentation Is Common in a Large ATTRv Cohort (#356)
Speaker:
Victor Rodrigues Pontes (Brazil)
Shorter, But Not Equal: Patient-Reported Trends in ATTRwt Diagnosis, 2022–2025 (#357)
Speaker:
Kristen Hsu (USA)
Concurrent Light Chain and Transthyretin Amyloidosis in the Bone Marrow of a Patient With Evidence of Renal and Cardiac Involvement (#358)
Speaker:
Mette Niemann Christoffersen (Denmark)
Rapid Hematological Response to Belantamab Mafodotin Enables Heart Transplant in Cardiac AL Amyloidosis (#359)
Speaker:
Colin Kloock (USA)
An Indirect Comparison of the Efficacy of Acoramidis and Tafamidis on Cardiovascular Outcomes and Mortality in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Results From an Anchored Matching-Adjusted Analysis of ATTRibute-CM and ATTR-ACT (#360)
Speaker:
Kevin M. Alexander (USA)
Therapeutic Challenges Faced by People With ATTR in Brazil (#361)
Speaker:
Fabio Almeida (Brazil)
Diagnostic Sensitivity of Different Biopsy Sites and Combined Sampling Strategies in AL Amyloidosis in a Reference Center (#362)
Speaker:
Camila Peña (Chile)
Prevalence and Prognostic Impact of Significant Valvular Heart Disease in Wild-Type Transthyretin Cardiac Amyloidosis (#363)
Speaker:
Santiago Decotto (Argentina)
Hereditary Gelsolin Amyloidosis in France: A Nationwide Multicenter Retrospective Study (#364)
Speaker:
Andoni Echaniz-Laguna (France)
Retrospective Study Evaluating Cardiac Biomarkers in Patients With AL Amyloidosis (#365)
Speaker:
Mike Petrassi (USA)
Amyloid Typing by Combined Laser Capture Microdissection and Mass Spectrometry (#366)
Speaker:
Alex Soltermann (Switzerland)
Prospective Validation of a Predictive Model and Simplified Score for the Diagnosis of Transthyretin Cardiac Amyloidosis: The PROVALTA Study (#367)
Speaker:
Rocio Eiros Bachiller (Spain)
Efficacy and Safety of Vutrisiran in South American Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post Hoc Analysis of HELIOS-B (#368)
Speaker:
Juan Pablo Costabel (Argentina)
Musculoskeletal Events and Risk of Amyloidosis in the General Population: Three Prospective Cohort Studies Totaling 8,731,287 Individuals (#369)
Speaker:
Søren N Rønborg (Denmark)
Neurological Characteristics of ATTR-PN and Mixed Phenotype Across Age and Sex in a Multi-National Study (#370)
Speaker:
Katrin Hahn (Germany)
Extracellular Chaperones Amplify the Intrinsic Variability of Immunoglobulin Light Chains Amyloidogenesis (#371)
Speaker:
Francesca Lavatelli (Italy)
Beyond the Heart: Peripheral Neuropathy in Wild-Type and p.Val142Ile Hereditary Transthyretin Amyloid Cardiomyopathy (#372)
Speaker:
Alejandra Gonzalez Duarte (USA)
Characterizing Dysautonomia in Patients With Cardiac ATTR Amyloidosis (#373)
Speaker:
Alejandra Gonzalez Duarte (USA)
Prognostic Impact of Coronary Flow Reserve in Transthyretin Cardiac Amyloidosis Independent of Coronary Calcium Burden (#374)
Speaker:
Pedro Passaglia Neto (Brazil)
Prognostic Value of Right Ventricular Systolic Function in Cardiac Amyloidosis (#375)
Speaker:
Luciana Ramirez Fontanarrosa (Argentina)
Fludarabine Exposure is Associated with CAR-T Kinetics in Nexicart-2 (#376)
Speaker:
Eugene Brailovski (USA)
Optimization of a Patient-Reported Outcome Measure for Clinical Use: Recent Advances in the Transthyretin Amyloidosis – Quality of Life Questionnaire (ATTR-QOL) (#377)
Speaker:
Kristen Hsu (USA)
Inhibition of Antibody Light Chain Aggregation by Transthyretin (#378)
Speaker:
Aizad Rana (USA)
Comparison of Each Cardiac Amyloidosis for Metal Element Deposition Using X-Ray Fluorescence (#379)
Speaker:
Tsuneaki Yoshinaga (Japan)
Budget Impact of Adding Acoramidis to Formulary for the Treatment of Transthyretin Amyloid Cardiomyopathy: A United States Health Plan Analysis (#380)
Speaker:
Liana Hennum (USA)
Enhancing Antibody Bioactivity and Amyloid Reactivity Using Novel Proline-Based Pan-Amyloid Reactive Peptides (#381)
Speaker:
Jonathan Wall (USA)
Treatment Patterns and Clinical Phenotypes in a National VA ATTR-CM Cohort Across Diagnostic and Therapeutic Eras (#382)
Speaker:
Liana Hennum (USA)
Combined Treatment With a TTR Silencer and Stabilizer in Late-Onset p.Val50Met Hereditary Transthyretin Amyloidosis With Mixed Phenotype: A Case Report (#383)
Speaker:
Mauricio Tomei (Argentina)
Prognostic Value of Right Ventricular Ejection Fraction by Cardiac Magnetic Resonance in Transthyretin Cardiac Amyloidosis (#384)
Speaker:
Florencia Cantora (Argentina)
Health Care Access and Diagnostic Experiences Among Black Patients With Transthyretin Amyloidosis in Cincinnati: A Qualitative Interview and Focus Group Study (#385)
Speaker:
Kevin Alexander (USA)
Improved Cardiac Outcomes With Daratumumab Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) Versus CyBorD Alone in Patients With Newly Diagnosed AL Amyloidosis: Results of the ANDROMEDA Study (#386)
Speaker:
Timon Hansen (Germany)
Natural History, Hospitalizations, and Causes of Death in ATTRv V30M Amyloidosis: An Endemic European Cohort (#387)
Speaker:
Inés Losada (Spain)
From Deposit to Damage: Renal Chronicity as a Missing Piece in Al Amyloidosis Risk Stratification (#388)
Speaker:
Luis Quintana (Spain)
Aβ2m Amyloidosis Revisited: From Declining Incidence to New Challenges in an Aging Dialysis Population (#389)
Speaker:
Junichi Hoshino (Japan)
ATTR Amyloidosis and Musculoskeletal Comorbidities: Referral Patterns and a Novel Diagnostic Tool Highlighting the Gatekeeper Role in Early Diagnosis (#390)
Speaker:
Arne Decramer (Belgium)
Phenotype Characterization of p.Glu109Lys Hereditary Transthyretin Amyloidosis in a Non-Endemic Area (#391)
Speaker:
Larissa Pianta Alves (Brazil)
A Multiparametric Echocardiographic Algorithm for the Differential Diagnosis of Pathological Left Ventricular Hypertrophy (#392)
Speaker:
Saoussen Antit (Tunisia)
Untargeted Serum Metabolomics Identifies Candidate Metabolic Signatures Associated With Disease Expression in Variant Transthyretin Amyloidosis (#393)
Speaker:
Inés Losadas (Spain)
Sex-Related Differences in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM-CM) Receiving Eplontersen: Results From the CARDIO-TTRansform Study (#394)
Speaker:
Margot K. Davis (Canada)
Genetic Background of Hereditary Transthyretin Amyloidosis in Turkey: 30-Year Experience From a Referral Center (#395)
Speaker:
Arman Cakar (Türkiye)
Long-term Clinical and Laboratory Follow-up in a Family With Primary Hereditary AA Amyloidosis Treated With Anti-interleukin 6 Therapy (#396)
Speaker:
Jakub Sikora (Czech Republic)
Utilization of BCMA-directed CAR-T in AL Amyloidosis: Early Toxicity Outcomes (#397)
Speaker:
Anita D’Souza (USA)
Clinical and Economic Burden of Delayed Diagnosis in Transthyretin Amyloid Cardiomyopathy: A U.S. Claims-Based Analysis (#398)
Speaker:
Shreya Yalamanchili (USA)
Screening Biopsies for Diagnosis of ATTR Amyloidosis (#399)
Speaker:
Jack Carruthers (United Kingdom)
Ten-Year Changes in the Access of Diagnostic Methods and Treatment for Systemic AL Amyloidosis in Uruguay: A Nationwide Survey and Historical Comparison (#400)
Speaker:
Lucía Pérez Baliero (Uruguay)
eGFR Dip Thresholds and Clinical Outcomes with Acoramidis: A Sensitivity Analysis From ATTRibute-CM (#401)
Speaker:
Daniel P. Judge (USA)
ATTR-QOL Captures Patient-Reported Disease Burden in Wild-type Transthyretin Amyloid Cardiomyopathy (#402)
Speaker:
Sie Kronborg Fensman (Denmark)
Tracing the Biophysical and Sequence Determinants of Light Chain Amyloid Formation (#403)
Speaker:
Frederic Rousseau (Belgium)
AA Amyloidosis of Multiple Causes: Analysis of 115 Patients From the French National Cohort (#404)
Speaker:
Sophie GEORGIN-LAVIALLE (France)
Demographic, Genetic, and Multisystemic Characterization of Patients With Hereditary Transthyretin Amyloidosis, Results From a Longitudinal Cohort Study: Twelve Different Genotypes in the Mexican Population (#405)
Speaker:
Alechka Melisa Arumir Lira (Mexico)
Sex-Related Differences in 99mTc-Pyrophosphate Uptake Patterns in Patients With Transthyretin Cardiac Amyloidosis (#406)
Speaker:
Adriana Puente Barragan (Mexico)
Epidemiological and Clinical Profile of Patients With AL Amyloidosis in a Brazilian Tertiary Center (#407)
Speaker:
Lucas Moraes (Brazil)
The Role of the General Practitioner in the Screening and Follow-up of Patients With ATTR Amyloidosis: A First Overview and Practical Recommendations (#408)
Speaker:
Flore Dewulf (Belgium)
Prefibrillar and Fibrillar TTR81–127 Induce Divergent Transcriptional Responses in Cultured Human Fibroblasts (#409)
Speaker:
YUNJIA ZHOU (Japan)
sST2 and GDF-15 as Biomarkers of Cardiac Involvement in Hereditary Transthyretin Amyloidosis (#410)
Speaker:
Intissar Anan (Sweden)
Evidence of 10 Years of Therapy With the First mRNA Silencer, Patisiran, in a Hereditary Transthyretin Amyloidosis Cohort (#411)
Speaker:
Karla Cárdenas-Soto (Mexico)
eGFR Dip After Acoramidis Initiation and Acoramidis-Associated Clinical Benefits in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) With and Without Atrial Fibrillation: Findings From the ATTRibute-CM Trial (#412)
Speaker:
Daniel P. Judge (USA)
Prevalence and Prognostic Impact of Atrial Fibrillation at Diagnosis in Patients With Transthyretin Cardiac Amyloidosis (#413)
Speaker:
Pedro Touzas Guglielmone (Argentina)
Safety of Performing Endomyocardial Biopsy in Patients With Suspected Amyloid Cardiomyopathy (#414)
Speaker:
Stéphanie Schwarting (Germany)
A Novel Amyloid type: Alpha-1 Antitrypsin Amyloid in a Well-Differentiated Neuroendocrine Tumor of the Pancreas (#415)
Speaker:
Ellen McPhail (USA)
Fatty Acid and Inflammatory Alterations in AL Amyloidosis Across Bone Marrow, Circulation, and Peripheral Tissue (#416)
Speaker:
Oshrat Hershkovitz-Rokah (Israel)
Kappa Light Chain Isotype Predicts High-Quality Cardiac Response in AL Amyloidosis Patients Achieving Hematologic Complete Response (#417)
Speaker:
Xinyi Xiong (China)
A Novel Amyloid type: Gastrin Amyloid in a Neuroendocrine Carcinoma (#418)
Speaker:
Ellen McPhail (USA)
Expanding the Genotypic Spectrum of Hereditary Transthyretin Amyloidosis in Brazil: Compound Heterozygosity and Homozygous Genotypes in a Multicenter Cohort (#419)
Speaker:
Natalya Goncalves Pereira (Brazil)
Phenotypic Variability in Patients Heterozygous for the TTR p.Val142Ile Variant and an Additional TTR Variant: A Brazilian Case Series (#420)
Speaker:
Victor Rodrigues Pontes (Brazil)
Further Preclinical Characterization of Zamubafusp Alfa (AT-02) Bioactivity With a Focus on Light Chain (AL) Amyloidosis (#421)
Speaker:
Jonathan Wall (USA)
Machine Learning Based Analysis of Measurable Residual Disease and Clinical Outcomes After Hematologic Complete Response in AL Amyloidosis (#422)
Speaker:
Andrew Staron (USA)
Safety and Efficacy of Sargramostim in Combination With D-VCd (daratumumab, bortezomib, cyclophosphamide, dexamethasone) Egimen in Untreated Patients With Al Amyloidosis: Results From STARLIGHT Phase 2 Multicenter Clinical Trial (#423)
Speaker:
Krzysztof Jamroziak (Poland)
The β-strand B and CDR1 Modulate the Amyloid Aggregation of λ6 Light Chains (#424)
Speaker:
Luis Del Pozo-Yauner (USA)
Spectrum of TTR Variants and Clinical Baseline Data in Patients With ATTR Amyloidosis: Data From a Tertiary Amyloidosis Center in Germany (#425)
Speaker:
Katrin Hinderhofer (Germany)
Reliability and Validity of the Transthyretin Amyloidosis – Quality of Life Questionnaire (ATTR-QOL) Symptom Scales (#426)
Speaker:
Kaitlin LaGasse (USA)
Development and Validation of the deteCTTAR Score for Pre-test Risk Stratification of ATTR Cardiomyopathy (#427)
Speaker:
Magali Gobbo (Argentina)
Tafamidis Treatment Significantly Reduces the Risk of Recurrent Cardiovascular-Related Hospitalization in Patients With Early Stage Transthyretin Amyloid Cardiomyopathy (#428)
Speaker:
Valentina Marino (Italy)
Functionally Limiting Symptoms and Inability to Independently Complete Activities of Daily Living Increase the Burden Felt by Caregivers to Patients With Transthyretin Amyloid Cardiomyopathy (#429)
Speaker:
Francesco Cappelli (Italy)
Comparative Characteristics of Patients With Cardiac Amyloidosis With and Without Monoclonal Gammopathy in the TTRACK Study Population (#430)
Speaker:
Francesco Cappelli (Italy)
Biochemical Analysis of Serum Immunoglobulin Heavy-Chain Aggregates Using Originally Developed Anti-Variable Region Antibodies in AH Amyloidosis (#431)
Speaker:
Ryusei Ozawa (Japan)
Overall Survival and Mortality Risks After Kidney Transplantation in AL Amyloidosis (#432)
Speaker:
Solos Jaturapisanukul (Thailand)
Anatomic Distribution of Amyloid on Kidney Biopsy and Renal Outcomes in AL Amyloidosis (#433)
Speaker:
Alec Seidman Sorsby (USA)
Earlier Diagnosis of Transthyretin Amyloid Cardiomyopathy Over Time: Temporal Trends from the Argentine Federation of Cardiology National Registry (#434)
Speaker:
Carlos Dumont (Argentina)
Application of 18F-Flutemetamol PET With Bone Scintigraphy to the Evaluation of Systemic Amyloidosis (#435)
Speaker:
Nagaaki Katoh (Japan)
Arginine Stabilizes Tetrameric Transthyretin and Suppresses Amyloid Fibril Formation Under Vitreous-Mimicking Conditions (#436)
Speaker:
Atsushi Fukunari (Japan)
Longitudinal Changes in Global Longitudinal Strain and Relative Apical Sparing in Cardiac Amyloidosis (#437)
Speaker:
Spyridon Gerovasileiou (Sweden)
An Interactive Dashboard Using Real-World Study Data to Inform Clinical Practice and Improve Quality of Care: Conducttor (#438)
Speaker:
Julian. D Gillmore (United Kingdom)
Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients With Transthyretin Amyloid Cardiomyopathy (#439)
Speaker:
Valentina Marino (Italy)
Anakinra-Derived Amyloidosis Occurs Across the Spectrum of IL-1-mediated Autoinflammatory Disease (#440)
Speaker:
Helen Lachmann (United Kingdom)
Cardiac Findings in ATTRv Patients Treated With RNA-Silencing Therapies (#441)
Speaker:
Simone Longhi (Italy)
Impact of Tafamidis on Transthyretin Concentration and its Relation to All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy: An Analysis From ATTR-ACT (#442)
Speaker:
Mathew Maurer (USA)
Body Composition and Nutritional Changes Before and After Autologous Stem Cell Transplantation in Patients With AL Amyloidosis (#443)
Speaker:
Phillip Scheinberg (Brazil)
Real-World Effectiveness of Tafamidis in a Contemporary, Matched Cohort of Patients With Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy (#445)
Speaker:
Mathew Maurer (USA)
Transforming First-Line Treatment of AL Amyloidosis: Real-World Outcomes With Daratumumab-VCD in Spain (#446)
Speaker:
Jose Miguel Mateos Perez (Spain)
A Bivalent Small-Ligand Inhibiting Transthyretin Amyloid Fibrillogenesis (#447)
Speaker:
Sofia Giorgetti (Italy)
Clinical Profiles and CIED Performance in Cardiac Amyloidosis Patients (#448)
Speaker:
Anna Dimoula (Greece)
Enhancing Diagnostic Accuracy of the T-Amylo Model and Score for Transthyretin Cardiac Amyloidosis: Results From the Provalta Study (#449)
Speaker:
Rocio Eiros Bachiller (Spain)
Frontline Dexamethasone Dose Intensity and Outcomes in AL Amyloidosis in the Era of Novel Agents (#450)
Speaker:
Eyal Lebel (Israel)
Regional Longitudinal Strain of the Left Ventricular Inferior Wall and Middle Segments Among Prognostic Factors of 12-Month Mortality in Cardiac Light Chain Amyloidosis (#451)
Speaker:
Jakub Malinowski (Poland)
Impact of Concomitant Multiple Myeloma on Presentation, Management and Survival in AL Amyloidosis (#452)
Speaker:
Elena Alejo (Canada)
Availability of Resources for the Diagnosis and Treatment of Amyloidosis in Latin America: Results of a Regional Survey of Specialists (#453)
Speaker:
Erika Brulc (Argentina)
The Israeli Experience With Proteomic Amyloid Typing (#454)
Speaker:
Enosh Askenasy (Israel)
Monoclonal Gammopathy of Renal Significance: Experience From Two Belgian University Hospitals (#455)
Speaker:
Ornella Rizzo (Belgium)
Questioning the Added Value of CPET Over Established Markers of Disease in ATTR-CM (#456)
Speaker:
Liam M Kidd (USA)
Left Atrial Strain as a Sensitive Marker of Early Cardiac Functional Improvement in Relation to Hematologic Response Depth in AL Amyloidosis (#457)
Speaker:
Ioannis Petropoulos (Greece)
B-Cell Maturation Antigen (BCMA)-Directed Bispecific Antibody (BsAb) Therapies in Al Amyloidosis (#458)
Speaker:
Ansel Fellman (USA)
Evolution of Echocardiographic Parameters During Tafamidis Therapy in Patients With Transthyretin Cardiac Amyloidosis: A Real-World Cohort Study (#459)
Speaker:
Angeliki Alifragki (Greece)
Daratumumab-CVD Therapy in IgM-associated Light Chain Amyloidosis: Clinical Characteristics and Outcomes (#460)
Speaker:
Suraj Vasudevan (United Kingdom)
Prevalence and Classification of Aortic Stenosis in Wild-type Transthyretin Amyloid Cardiomyopathy (#461)
Speaker:
Ali Hussein Jaber Mejren (Denmark)
Appropriate Use of CARI in Suspected ATTR-CM (#462)
Speaker:
Isabel Carvajal-Juarez (Mexico)
Chronic Kidney Disease Trajectory Prior to the Diagnosis of Wild-Type Transthyretin Cardiac Amyloidosis and Metabolic Parameters Associated With Outcomes (#463)
Speaker:
Krishna Allam (USA)
High Prevalence of Amyloid in Bone Marrow Biopsy Specimens in Patients With MGUS (#464)
Speaker:
Maria Picken (USA)
Socioeconomic Disparities in Transplant Access and Survival in AL Amyloidosis (#465)
Speaker:
Flores Weverling (Netherlands)
Quantitative Assessment of Cardiac Amyloid Burden by Tc99m-Pyrophosphate SPECT Correlates With Disease Severity in Transthyretin Amyloid Cardiomyopathy (#466)
Speaker:
Fernando Coneglian (Brazil)
Impact of a Dedicated Multidisciplinary Amyloidosis Center on Diagnosis and Treatment Timelines in AL Amyloidosis (#467)
Speaker:
Vitor Rodrigues (Brazil)
False-Positive Transthyretin Immunostaining in Amyloid Typing: Detection by Novel Monoclonal Antibodies and Confirmation by Proteomics (#468)
Speaker:
Yukako Shintani-Domoto (Japan)
BCMA Bispecific Antibodies in Relapsed/Refractory AL Amyloidosis: Clinical Experience in 3 Academic Belgian Centers (#469)
Speaker:
Marie-Christiane VEKEMANS (Belgium)
Real-World Outcomes of Second-Line Interventions in AL Amyloidosis After Frontline Daratumumab Failure: Characterizing Therapeutic Gaps (#470)
Speaker:
Paolo Milani (Italy)
Wild-Type and Variant Transthyretin Induce Cardiotoxicity in Primary Murine Cardiomyocytes via Downregulation of Oxphos Complexes (#471)
Speaker:
Angeliki Choustoulaki (Greece)
A Transgenic Mouse Model Recapitulates Human AL Amyloidosis-Associated Cardiac Proteome Remodelling (#472)
Speaker:
Francesca Lavatelli (Italy)
Galectin-3 as a Biomarker for ATTRv Amyloidosis: Cardiorenal Insights Across 99mTc-DPD Phenotyping (#473)
Speaker:
Jose Pedro Escaleira (Portugal)
Sequence-Based Prediction of Immunoglobulin Light Chain Toxicity: Benchmarking of Available in Silico Prediction Tools (#474)
Speaker:
Alice Nevone (Italy)
Feasibility of 20-minute Imaging With Tc-99 HMDP for ATTR Cardiomyopathy (#475)
Speaker:
Joseph Donohue (USA)
Clinical Presentation of Kidney AL Amyloidosis Varying by Light Chain Isotype: Data From a National Population-Based Biopsy Cohort (#476)
Speaker:
Hilde Jaeger Vasstrand (Norway)
Effects of TTR Cleavage and Interaction With Ligament Proteins in Amyloid Fibrillation Models (#477)
Speaker:
Gunilla Westermark (Sweden)
Left Atrial Reservoir Strain and Atrial Stiffness Correlates With Markers of Disease Severity in ATTR Amyloid Cardiomyopathy (#478)
Speaker:
Fernando Coneglian (Brazil)
Empowering Patients With AA Amyloidosis Through Therapeutic Education (#479)
Speaker:
Sophie GEORGIN-LAVIALLE (France)
Proteomic Typing of Amyloidosis by Mass Spectrometry in Formalin-Fixed Paraffin-Embedded Tissue: Initial Experience From a Local Interdisciplinary Workflow (#480)
Speaker:
Mercedes Juarez Araoz (Argentina)
[99mTc]Tc-DPD Quantitative SPECT/CT Profile in ATTR Amyloidosis: Mapping Fibrillar Heterogeneity (#481)
Speaker:
Jose Pedro Escaleira (Portugal)
Autologous Stem Cell Transplantation for AL Amyloidosis: Zero 100-Day Transplant- Related Mortality and High Deep Response Rates in a Single-Center Brazilian Cohort (#482)
Speaker:
Phillip Scheinberg (Brazil)
Long-Term Evolution of Hereditary Transthyretin Amyloidosis (Val142Ile) With Exclusively Neurologic Presentation (#483)
Speaker:
Marina Santos (Brazil)
Database Analysis of the Largest Series of Amyloidosis Typing by Mass Spectrometry in the Southern Hemisphere (#484)
Speaker:
Jussara-Bianchi Castelli (Brazil)
Diagnostic Odyssey in Hereditary Transthyretin Amyloidosis: A Nationwide Brazilian Cohort (#485)
Speaker:
Natalya Goncalves Pereira (Brazil)
Long-Term Follow-Up of Venetoclax Therapy in AL Amyloidosis (#486)
Speaker:
Divaya Bhutani (USA)
Multimodality Cardiac Assessment in Hereditary Transthyretin Amyloid Cardiomyopathy: A Brazilian Cohort (#487)
Speaker:
Natalya Goncalves Pereira (Brazil)
Advancing Early Diagnosis of ATTR Amyloidosis Through Detection of Circulating Aggregates (#488)
Speaker:
Elisia Paiz (USA)
Unmoderated Posters - Wednesday
Unmoderated Posters - Wednesday
Multimodality Imaging in Monoclonal Gammopathy of Undetermined Significance and ATTR Wild-Type Cardiac Amyloidosis (#489)
Speaker:
Yrving Ernesto Figueredo Peguero (Cuba)
Navigating the Expanding ATTR Medication Landscape: Key Pharmacologic Considerations When Transitioning Agents (#490)
Speaker:
Spencer Martin (Canada)
Recognise the pATTeRn in ATTR: A Mnemonic to Help Clinicians With No or Limited Experience in the Disease Suspect ATTR Amyloidosis (#491)
Speaker:
Phillip Scheinberg (Brazil)
ENTRUST-AL Trial in Progress: A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig Compared With Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Patients With Newly Diagnosed (ND) Amyloid Light Chain (AL) Amyloidosis (#492)
Speaker:
Efstathios Kastritis (Greece)
Non-Pharmacological Healthcare Resource Utilization in Systemic Amyloidosis: A Multicenter Comparative Study (#493)
Speaker:
Marcelina Carretero (Argentina)
External Validation of a Predictive Model for Diagnosing Transthyretin Cardiac Amyloidosis in Suspected Cases (#494)
Speaker:
Santiago Decotto (Argentina)
Efficacy of Daratumumab-Based Treatment in Brazilian Patients With Systemic Light Chain (Al) Amyloidosis: A Real-World Single-Center Retrospective Study (#495)
Speaker:
Moysés Porto Soares (Brazil)
Designing Personalized Therapies in Renal Biopsies From Patients With AL (Light Chain-Associated)-Amyloidosis (#496)
Speaker:
Guillermo A Herrera (USA)
Development of Hereditary Transthyretin Amyloidosis Symptoms After Domino Liver Transplantation: A Case Report in Brazil (#497)
Speaker:
Lorena Gianizeli Paganotti (Brazil)
AL Amyloid Myopathy: A Diagnosis Challenge (#498)
Speaker:
Isabel Moro (Uruguay)
Coexistence of p.Val50Met and p.Val142Ile Pathogenic Variants in the TTR Gene: A Phenotypic Challenge in Hereditary Amyloidosis (#499)
Speaker:
Pedro Passaglia (Brazil)
The Diverse Nephrological Spectrum of Hereditary ATTRv Amyloidosis in Patients of Thracian/Bulgarian Ancestry: A Three-Variant Case Series From Turkiye (#500)
Speaker:
Rezzan Eren Sadioglu (Türkiye)
Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis (#501)
Speaker:
Ashutosh D. Wechalekar (United Kingdom)
Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: The Cares Trials (#502)
Speaker:
Candida Cristina Quarta (USA)
Building the First Multidisciplinary Amyloidosis Committee in the Saudi MOH (HHC–KSMC Experience) (#503)
Speaker:
Dr. FAYEZ AL-ZUBAIR (Saudi Arabia)
Novel Variant in Transthyretin Cardiac Amyloidosis: Asp58Glu (#504)
Speaker:
Larissa Bruscky (Brazil)
Upgrading to Cardiac Resynchronization or Left Bundle Branch Pacing in ATTR-Cardiomyopathy (#505)
Speaker:
Clea González-Maniega (Spain)
Real-World Clinical and Prognostic Outcomes in Patients With Wild-Type Transthyretin Cardiac Amyloidosis Treated With Vutrisiran (#506)
Speaker:
José Ángel Urbano-Moral (Spain)
Hereditary Transthyretin Amyloidosis (ATTRv) in Latin America: A Multicenter Retrospective Study from Argentina, Brazil, Bolivia & Mexico (#507)
Speaker:
Maria Adela Aguirre (Argentina)
Localized Gastric AL Amyloidosis With Profound Mucosal Involvement: Successful Response to Systemic Treatment (#508)
Speaker:
Charlotte Toftmann Hansen (Denmark)
Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy: Real-World Evidence of Lower Transthyretin Silencer Therapy Initiation With Acoramidis (#509)
Speaker:
Richard F. Wright (USA)
Functional Stability Measured With 6MWD in Patients Treated With Tafamidis vs Placebo: Post-Hoc Analysis From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (#510)
Speaker:
Pablo Garcia-Pavia (Spain)
Clinical and Multimodal Neurophysiological Features of Hereditary Transthyretin Amyloidosis in a Non-Endemic Cohort (#511)
Speaker:
Camila Peña (Chile)
Female Wild-Type Transthyretin Cardiac Amyloidosis Across a National Registry: Prevalence, Clinical Phenotype, and Center-Level Heterogeneity (#512)
Speaker:
zaroui amira (France)
Assessment of Vagal Nerve Dysfunction in Amyloidosis Through Sham Feeding (#513)
Speaker:
Timothy Woodward (USA)
Clinical Spectrum and Diagnostic Pathway of Systemic Amyloidosis in a Multidisciplinary Referral Center in Brazil (#514)
Speaker:
Marcus Simoes (Brazil)
Hub-and-Spoke Model Implementation for Early Diagnosis and Treatment of Systemic Amyloidosis in Structurally Weak Regions in Germany: A Study Protocol (#515)
Speaker:
Katrin Hahn (Germany)
Diffuse Tracheobronchial Amyloidosis Presenting as Prolonged Weaning Failure (#516)
Speaker:
Lucas Bujan Molins (Argentina)
Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt-CM) (#517)
Speaker:
Ali Hussein Jaber Mejren (Denmark)
Acoramidis Reduces Risk of Cardiovascular-Related Mortality and Hospitalization in Female Patients With Transthyretin Amyloid Cardiomyopathy (#518)
Speaker:
Margot Davis (Canada)
Mapping Diagnostic Gaps in Suspected Cardiac Amyloidosis (CA): A Service Evaluation of DPD Scintigraphy, Echocardiographic Recognition and AL Exclusion (#519)
Speaker:
Brandon Xian Ch'ng (United Kingdom)
Prior Autoimmune Disease Reshapes the Clonal Plasma-Cell Transcriptome and Remodels the Bone Marrow Microenvironment in Immunoglobulin Light-Chain Amyloidosis (#520)
Speaker:
Yang Liu (China)
The Safety and Efficacy of Sonrotoclax Combined With Dexamethasone With or Without Daratumumab in Patients With T(11;14) Primary Systemic Light Chain Amyloidosis: A Study Protocol (#521)
Speaker:
Yang Liu (China)
Phenotype Characteristics of Romanian Patients Carrying the TTR Ile107Val Variant (#522)
Speaker:
Andreea Jercan (Romania)
Cardiac and Liver Amyloidosis in Advanced Kidney Disease: Diagnostic Challenges (#523)
Speaker:
Tarek Ashour (USA)
Historical Portuguese Migration From Northen Portugal and Geographical Distribution of the P. Val50Met Variant in Argentina (#524)
Speaker:
Ariel Villagra Coco (Argentina)
Closing the Diagnostic Gap: Multistakeholder Recommendations for Genetic Testing and Counseling in Adult-Onset Rare Diseases (#525)
Speaker:
Enrique A. Berríos Bárcenas (Mexico)
Comparative Efficacy of Vutrisiran and Acoramidis in ATTR-CM: A Matching-Adjusted Indirect Comparison (#526)
Speaker:
Ronald Witteles (USA)
Structural Similarities Between AL Amyloid Fibrils Are Driven by a Subset of Residues (#527)
Speaker:
Parker Bassett (USA)
The Role of Nutritional Status, Measured by Serum Albumin, as a Prognostic Factor in Wild-Type Transthyretin Amyloidosis (#528)
Speaker:
Florencia Cantora (Argentina)
Case Report: Successful Case of Desensitization for Hypersensitivity With Inotersen (#529)
Speaker:
Mauricio Tomei (Argentina)
Prophylactic Tocilizumab in Patients Treated With Bispecific T Cell Engaging Antibodies for AL Amyloidosis (#530)
Speaker:
Udit Yadav (USA)
Treatment Patterns in Newly Diagnosed Patients With Transthyretin Amyloid Cardiomyopathy in the United States: Results From a Real-World Study Show Transthyretin Stabilizers Are the Predominant First-Line Treatment (#531)
Speaker:
Liana Hennum (USA)
Comparison of the Effectiveness and Safety of Diflunisal and Tafamidis for Transthyretin Amyloidosis Cardiomyopathy (#532)
Speaker:
Timothy Scully (Australia)
ACO-MONITOR: An Observational Study Evaluating the Acceptance and Feasibility of a Digital Remote-Monitoring Tool for Patients With ATTR-CM (#533)
Speaker:
Giovanni Palladini (Italy)
Health-Related Quality of Life (HRQoL) in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Outpatient Worsening Heart Failure (oWHF): A Post-hoc Analysis of the ATTRibute-CM Trial (#534)
Speaker:
Laura Obici (Italy)
Impact of Early GI Diagnosis in Amyloidosis (#535)
Speaker:
Timothy Woodward (USA)
Early Reduction of Heart Failure Events With Acoramidis: A Time-to-Benefit Analysis of ATTRibute-CM (#536)
Speaker:
Mazen Hanna (USA)
Tafamidis in Patients With Advanced Chronic Kidney Disease (#537)
Speaker:
Clea González-Maniega (Spain)
One-Year Multidomain Disease Progression in a Native Sub-Saharan African Cohort With Transthyretin Amyloid Cardiomyopathy (#538)
Speaker:
Carlos M Penate (Mexico)
NLRP3 Inflammasome Activation in Cardiac AL Amyloidosis and Its Association With Early Mortality: A Prospective Pilot Study (#539)
Speaker:
Camila Peña (Chile)
Clinical Characteristics and Outcomes of a Chilean Cohort of Patients With Systemic AL Amyloidosis (#540)
Speaker:
Camila Peña (Chile)
Establishing a National Amyloidosis Network and Multidisciplinary Team Meeting (MDT) (#541)
Speaker:
Tale Norbye Wien (Norway)
Intrafamilial Phenotypic Variability in Patients Homozygous for the TTR p.Val142Ile Variant: A Brazilian Case Series (#542)
Speaker:
Victor Rodrigues Pontes (Brazil)
Burden of Symptoms in Transthyretin Amyloid Cardiomyopathy: A United States Physician Survey Describing Gender Perspectives (#543)
Speaker:
Ann Willet (USA)
Risk-Stratifying Suspected ATTR-CM Before DPD Scintigraphy: A Service Evaluation of Published Scores (#544)
Speaker:
Brandon Xian Ch'ng (United Kingdom)
Comparative Efficacy and Safety of Tafamidis Versus Acoramidis in Transthyretin Amyloid Cardiomyopathy: A Matching-Adjusted Indirect Comparison (#545)
Speaker:
Stefano Perlini (Italy)
Temporal Identification of Early Comorbidities for Enhanced Detection of ATTRwt-CM: A Medicare Analysis (#546)
Speaker:
Ann Willet (USA)
Navigating AL Amyloidosis During the First Six Months After Diagnosis: A Longitudinal Family-Focused Qualitative Study (#547)
Speaker:
Anne Møller Clausen (Denmark)
Rationale and Design of the Multinational Non-Interventional Study Assessing Frailty in Patients With ATTR-CM With and Without Tafamidis Treatment (#548)
Speaker:
Francesco Cappelli (Italy)
Describing Burden for Transthyretin Amyloid Cardiomyopathy Patients and Their Caregivers in the United States: A Real-World Survey (#549)
Speaker:
Janice Chung (USA)
Risk of Multiple Cardiovascular-Related Hospitalizations and of All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings From ATTRibute-CM Using Multistate Modeling (#550)
Speaker:
Kevin M. Alexander (USA)
Amyloid Typing by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis of Unfractioned Unfixed Endomyocardial Biopsies in Patients With Suspected Cardiac Amyloidosis (#551)
Speaker:
Serena Caminito (Italy)
The Journey to Diagnosis for Amyloidosis Patients in the United States: Contemporary Real-World Evidence From Medicare Claims (#552)
Speaker:
Kimberly F. Greco (USA)
Electrocardiographic Features and Evolution of Electrical Abnormalities in Patients With Transthyretin Cardiac Amyloidosis (#553)
Speaker:
Pedro Touzas Guglielmone (Argentina)
Prostatic Amyloidosis Involving Semenogelin-1: A Rare Case Illustrating the Importance of Techniques in Amyloid Typing (#554)
Speaker:
Alexia RINSANT (France)
Unusual Location and Presentation of Wild Type Transthyretin Amyloidosis: A Case Series (#555)
Speaker:
Yvonne Efebera (USA)
Defining the Penetrance of Amyloidosis in Asymptomatic Genotype Positive Relatives of V122I TTR Affected Patients (#556)
Speaker:
Pawel Pomianowski (USA)
Reversal of Radiotracer Uptake on Serial 99mTc-Pyrophosphate Scintigraphy in Familial Transthyretin Amyloidosis Following Disease-Modifying Therapy (#557)
Speaker:
Yvonne Efebera (USA)
Early eGFR Dip Following Acoramidis Initiation in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Is Not Accompanied by Clinically Meaningful Changes in Laboratory Measures or Blood Pressure: An ATTRibute-CM Analysis (#558)
Speaker:
Julian D. Gillmore (United Kingdom)
Clinical Phenotype and Outcomes of AL Amyloidosis Meeting Contemporary Multiple Myeloma Criteria (#559)
Speaker:
Okan Cetin (USA)
The Importance of Whole-Gene Sequencing in TTR Over Familial Variant Testing in Hereditary Transthyretin Amyloidosis (#560)
Speaker:
Karen Zepeda León (Mexico)
Atrial Fibrillation Is Associated with Poor Survival in Patients With Wild-type ATTR Cardiomyopathy (#561)
Speaker:
Gregor Zemljic (Slovenia)
Real-World Longitudinal Evaluation of Tafamidis Therapy in ATTR Cardiac Amyloidosis: A 12-Month Retrospective Cohort Study (#562)
Speaker:
Robert Holley (Australia)
Genotype–Phenotype Dissociation in Homozygous Transthyretin Val142Ile Amyloidosis (#563)
Speaker:
Larissa Bruscky (Brazil)
Cardiac Amyloidosis in a Tertiary Referral Center in South America: Diagnostic Delay, Clinical Presentation, and Outcomes (#564)
Speaker:
Martina Perdomo (Uruguay)
eGFR Dip After Acoramidis Initiation and Acoramidis-Associated Clinical Benefits in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) With and Without Diabetes: Findings From the ATTRibute-CM Trial (#565)
Speaker:
Margot K. Davis (Canada)
Hereditary Apolipoprotein A-I Amyloidosis: A Case Report Highlighting Multisystem Disease and Familial Transplant Implications (#566)
Speaker:
Pawel Pomianowski (USA)
Oral and Systemic Manifestations of Light-Chain, Variant and Wild-Type Transthyretin Amyloidosis (#567)
Speaker:
Mauricio Neves Gomes (Brazil)
Stabilization of Neurologic Progression With Tafamidis in Transthyretin Amyloidosis with a Mixed Phenotype: A Real-World Analysis (#568)
Speaker:
Laura Obici (Italy)
Real-World Adherence and Persistence of Eplontersen in Patients With ATTR (#569)
Speaker:
Sumeet Mitter (USA)
Somatic Mutations Destabilize the 40–60aa Loop and Drive Amyloid Formation of the JD-V2-14 Light Chain (#570)
Speaker:
Aaron Feinstein (USA)
Detailed Pathophysiological Analysis of an AH Amyloidosis Patient With Severe Hepatic Amyloid Deposits (#571)
Speaker:
Ryusei Ozawa (Japan)
Prognostic Impact of Cardiac Magnetic Resonance Imaging in Patients With Heart Failure and Left Ventricular Hypertrophy (#572)
Speaker:
Daniel Lavall (Germany)
Beyond Neuropathy and Cardiomyopathy: Musculoskeletal Manifestations in ATTRv p.Ala101Val Amyloidosis (#573)
Speaker:
CLEONISIO LEITE RODRIGUES (Brazil)
Real-Wold Experience With Cesnicabtagene Autoleucel (ARI0002h), An Academic BCMA‑Directed CAR T‑Cell Therapy, in Relapsed/Refractory Light‑Chain Amyloidosis (#574)
Speaker:
Jose Miguel Mateos Perez (Spain)
Multicenter Comparison of Mass Spectrometry–Based Amyloid Typing in Subcutaneous Abdominal Fat Tissue (#575)
Speaker:
Hans Nienhuis (Netherlands)
Stem Cell Transplantation in AL Amyloidosis: A Two-Center Argentine Experience (#576)
Speaker:
Martin Milanesio (Argentina)
Real-World Characteristics, Treatment Patterns and Outcomes of Patients With Concomitant AL Amyloidosis and Multiple Myeloma (#577)
Speaker:
Wolfgang Willenbacher (Austria)
ESCAN: Evaluation and Follow-up Plan for Hereditary ATTRv Amyloidosis (#578)
Speaker:
Gisela Zanga (Argentina)
Histopathological and Biochemical Analysis of Hereditary Transthyretin Amyloidosis Long After Liver Transplantation: An Autopsy Case (#579)
Speaker:
Masao Imura (Japan)
A Variant, a Syndrome, and a Suspicion: The Diagnostic Dilemma of Severe Progressive Sensorimotor Polyneuropathy With Dysautonomia and TTR Arg123His Variant (#580)
Speaker:
Gisela Zanga (Argentina)
Multimodality Imaging for Early Detection of Hereditary Transthyretin Amyloidosis Cardiomyopathy in a p.Ala39Asp TTR Variant Carrier: A Case Report (#581)
Speaker:
Larissa Pianta Alves (Brazil)
Trends in the Prevalence and Treatment of Transthyretin Amyloidosis in Australia and New Zealand – An updated “Snapshot” From Australian Amyloidosis Network-Affiliated Centres (#582)
Speaker:
Paul Geenty (Australia)
Clinical and Epidemiological Characteristics of Patients With AL Amyloidosis at a Public Tertiary Referral Hospital in the Federal District, Brazil (#583)
Speaker:
Jessica Oliveira (Brazil)
When PTLD/IDD-LPD leads to Amyloidosis: A Rare Complication After Pediatric Kidney Transplantation (#584)
Speaker:
Claudius Hammer (Germany)
Investigating the Role of Glycosylation in the Amyloidogenicity of Kappa Immunoglobulin Light Chains (#585)
Speaker:
Alessio Lampis (France)
Patient Characteristics, Clinical Variables, and Quality-Of-Life in Patients With Transthyretin Amyloidosis: A Maesttro Interim Analysis (#586)
Speaker:
Martha Grogan (USA)
Accurate Assessment of Treatment Response in AL Amyloidosis Using Mass Spectrometry (#587)
Speaker:
Florencia Delgado (United Kingdom)
The Amyloid That Would Not Light Up: A Multimodality Imaging Diagnostic Journey (#588)
Speaker:
Flávio Hernique Valicelli (Brazil)
Renal Events in Patients With Transthyretin Amyloidosis Treated With Tafamidis: Comprehensive Evidence From Clinical Trials, Literature Review, and Post-Marketing Surveillance (#589)
Speaker:
Valentina Marino (Italy)
The Crucial Added Value of SPECT/CT at Cardiac Amyloid Radionuclide Imaging (CARI) (#590)
Speaker:
Simone Longhi (Italy)
Tafamidis Improves Survival in a Contemporary, Real-World Cohort of Patients From THAOS With Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy (#591)
Speaker:
Jonas Wixner (Sweden)
The Diagnostic Value of the 12-Lead ECG in Wild-Type Transthyretin Amyloidosis With Cardiac Involvement (#592)
Speaker:
Paolo Milani (Italy)
Consistency of T-Amylo Diagnostic Performance Across Patient Subgroups: The PROVALTA Study (#593)
Speaker:
Ines Toranzo Nieto (Spain)
Amyloid Detection in Tenosynovium: A Gateway to Diagnosing Systemic Amyloidosis (#594)
Speaker:
Andrew Staron (USA)
Comparison of the N_Latex and Freelite Free Light Chain Assays Within the Non-Invasive Diagnostic Algorithm for Wild-Type Transthyretin Amyloidosis (#595)
Speaker:
Martina Nanci (Italy)
Diagnostic Delay in Cardiac Amyloidosis: A Temporal Analysis of a Hospital-Based Cohort (#596)
Speaker:
Agustina Pilar Mendiguren (Argentina)
Tafamidis Reduces the Burden of New-Onset Atrial Fibrillation in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy (#597)
Speaker:
Gregor Zemljic (Slovenia)
Successful Simultaneous Heart-Kidney Transplant in Hereditary ATTR Cardiac Amyloidosis and Renal Failure (#598)
Speaker:
Rebecca Conley (USA)
Elranatamab as a Bridge to Orthotopic Heart Transplantation in Advanced Cardiac AL Amyloidosis (#599)
Speaker:
Grace Ferri (USA)
Feasibility and Preliminary Convergent Validity of a Digital Short Patient-Reported Outcome Questionnaire in AL Amyloidosis: A Pilot Study (#600)
Speaker:
Tobias Dittrich (Germany)
Serial Time-Harmonic Elastography for Monitoring Myocardial Stiffness Under Disease-Modifying Therapy in ATTR Cardiomyopathy: A Proof-Of-Concept (#601)
Speaker:
Gina Barzen (Germany)
Prevalence, Presentation, and Management of Sustained Ventricular Tachycardia in Transthyretin Amyloid Cardiomyopathy (#602)
Speaker:
Thomas Weiss (Denmark)
Advanced Echocardiographic Assessment and Prognostic Insights of Tafamidis in ATTR-CM (#603)
Speaker:
Simone Longhi (Italy)
Optimizing Standardized Systolic Blood Pressure Measurement and Thresholds for Risk Stratification in AL Amyloidosis (#604)
Speaker:
Georgios Zervas (Greece)
Clinical Value of Post-treatment Assessment of Peripheral Vascular and Hemodynamic Markers in AL Amyloidosis (#605)
Speaker:
Ioannis Petropoulos (Greece)
Arterial-Myocardial Coupling in Primary AL Amyloidosis. A Validation Study of Vascular Involvement (#606)
Speaker:
Raphael Patras (Greece)
Beyond Age: Recognizing Early-Onset Wild-Type Transthyretin Amyloidosis (#607)
Speaker:
Tracy Joshi (USA)
Active Pharmacovigilance and Therapeutic Adherence to Tafamidis in Patients With Transthyretin Amyloidosis (ATTR) (#608)
Speaker:
Carlos Jesús Rodríguez-Escárcega (Mexico)
Improving Treatment Access for AL Patients With Outpatient Bispecific Antibody Programs (#609)
Speaker:
Sandy Mazzoni (USA)
Hereditary Transthyrretin Amyloidosis (ATTR) Caused by p.Arg54Gly Variant (#610)
Speaker:
Meletios-Athanasios Dimopoulos (Greece)
Risk Stratification in Cardiac Amyloidosis Using Comprehensive Echocardiography: Experience From a Latin America Referral Center (#611)
Speaker:
María Cecilia Escalante Seyffert (Mexico)
Liver Stiffness Measurement as an Independent Prognostic Marker in AL Amyloidosis (#612)
Speaker:
Andreea Jercan (Romania)
Successful Heart Transplantation Following Chimeric Antigen T-cell Therapy for AL amyloidosis: A Case Report (#613)
Speaker:
Eugene Brailovski (USA)
Preliminary Results of Congo Red Fluorescence Microscopy and Digital Image Analysis in Spontaneous Feline AA Amyloidosis (#614)
Speaker:
Melissa Milazzo (Italy)
Renal Safety of Diflunisal in Patients With Hereditary ATTR Amyloidosis Polyneuropathy: Post Hoc Analysis from the 24-Month Pivotal Phase 3 Trial (NCT00294671) (#615)
Speaker:
Jonas Wixner (Sweden)
Mass Spectrometry Reveals Discordant Light Chain Typing in Systemic AL Amyloidosis with Potential Therapeutic Implications (#616)
Speaker:
Pedro Garibaldi (Brazil)
Impact of MRD in the Outcome of Patients With Advanced Cardiac Light Chain (AL) Amyloidosis (#617)
Speaker:
Foteini Theodorakakou (Greece)
Genetic Variant in HAVCR2/TIM-3:The Association With AA Amyloidosis and a Rapid Kidney Function Decline Suggest Pathogenicity (#618)
Speaker:
Ana Cunha (Portugal)
NF-κB–ICAM-1 Axis Drives Cardiovascular Toxicity in AL Amyloidosis (#619)
Speaker:
Panagiota-Efstathia Nikolaou (Greece)
Biomarker-Guided Patient Selection for Anti-Amyloid Therapy in AL Amyloidosis (#620)
Speaker:
Mark Tulchinskiy (USA)
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis (#621)
Speaker:
Patrick Hagen (USA)
Bloodless Heart Transplantation After Impella 5.5 Support in Homozygous Hereditary Transthyretin Cardiomyopathy (#622)
Speaker:
Hamza Naveed (USA)
Surgically Recorded Musculoskeletal Manifestations Preceding Treated Transthyretin Cardiac Amyloidosis: A Nationwide Matched Case-Control Study (#623)
Speaker:
Marc-Antoine Delbarre (France)
AA Amyloidosis and Multiple Myeloma: A Diagnostic Pitfall (#624)
Speaker:
Imane Chajai (Morocco)
Diagnostic Performance of BNP, Global Longitudinal Strain, and Their Integrated Ratio for Cardiac Amyloidosis in a Prospective Cohort Study (#625)
Speaker:
Flavia Cortez Colosimo (Brazil)
Which Treatment Attributes Do Patients With Transthyretin Amyloid Cardiomyopathy Value Most? (#626)
Speaker:
Janice Chung (USA)
Health Care Professionals (HCPs) Perspectives on Treatment and Management of Light Chain (AL) Amyloidosis: An International Cross-Sectional Survey Study (#627)
Speaker:
Kristen Hsu (USA)
Impact of Tafamidis on Clinical Outcomes in Transthyretin Cardiac Amyloidosis (#628)
Speaker:
María García de Pedro (Spain)
The Residual TTR Hypothesis: A Scoping Review of the Mechanistic Rationale for Combining TTR Gene Silencers With TTR Stabilisers in ATTR Amyloidosis (#629)
Speaker:
Ines Ines Asuncion Losada Lopez (Spain)
Changes in Health Care Professional (HCP) Preferences for the Treatment of AL Amyloidosis Following Approval of Daratumumab-based Therapies (#630)
Speaker:
Kristen Hsu (USA)
Vutrisiran Treatment in Patients With Hereditary Transthyretin Amyloidosis and Cardiac Involvement: Real-World Experience at a Tertiary Referral Center (#631)
Speaker:
María García de Pedro (Spain)
Recognizing the Unrecognized: Amyloidosis Awareness Among Medical Interns in Uruguay: Results of an Educational Survey (#632)
Speaker:
Irina Silva Borghi (Uruguay)
Comprehensive Cardiac Phenotyping of Hereditary Transthyretin Amyloidosis Associated With the p. Ile127Val Variant: A Rare Mutation Identified in Northeastern Brazil (#633)
Speaker:
Fernando Coneglian (Brazil)
Genetic and Clinical Characterization of Six TTR Variants in Mexican Families with Hereditary Transthyretin Amyloidosis (#634)
Speaker:
María Cecilia Escalante Seyffert (Mexico)
Seven Years of a National Multidisciplinary Case Conference for AA Amyloidosis: Lessons From 138 Cases (#635)
Speaker:
Sophie GEORGIN-LAVIALLE (France)
Amyloidoma or Amyloidosis? (#636)
Speaker:
Haleema S Adil (USA)
Clinical Profile of Cardiac Amyloidosis in a Mexican Referral Center (#637)
Speaker:
María Cecilia Escalante Seyffert (Mexico)
Routine Clinical Assessment Using the 6-Minute Walk Test and KCCQ-12 in Transthyretin Cardiac Amyloidosis (#638)
Speaker:
Andre Casarsa Marques (Brazil)
Comprehensive Geriatric Assessment in Decision-Making in ATTR-CA (#639)
Speaker:
Mariana Gamboa Esparza (Mexico)
AL Amyloidosis With Negative Conventional Workup: Diagnosis Established by Proteomic Analysis (#640)
Speaker:
Jessica Oliveira (Brazil)
Psychopathology in Patients With Hereditary Transthyretin Amyloidosis (#641)
Speaker:
César Mauricio Fuentes Sánchez (Mexico)
Real-World Landscape of AL Amyloidosis and Treatment Patterns at a Tertiary Center in Asia (#642)
Speaker:
Melinda Tan (Singapore)